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Design of Radioiodinated Pharmaceuticals: Structural Features
Affecting Metabolic Stability towards in Vivo Deiodination
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Abstract: Radioiodinated pharmaceuticals are convenient trac-
ers for clinical and research investigations because of the rela-
tively long half-lives of radioactive iodine isotopes (i.e., 123I, 124I,
and 131I) and the ease of their chemical insertion. Their applica-
tion in radionuclide imaging and therapy may, however, be
hampered by poor in vivo stability of the C–I bond. After an
overview of the use of iodine in biology and nuclear medicine,
we present here a survey of the catabolic pathways for iodin-
ated xenobiotics, including their biodistribution, accumulation,
and biostability. We summarize successful rational improve-
1. Introduction
1.1. Iodine in Biology
Iodine is one of the heaviest essential elements present in living
organisms. In biology, iodine differs from other halogens, be-
cause it is also stored in the form of organoiodides, whereas
fluorine, bromine and chlorine are encountered mostly as salts
or free anions.[1] Iodine is taken in through the diet in its inor-
ganic iodide form and is absorbed in the gastrointestinal tract.
Once in the bloodstream, iodide accumulates in tissues that
express the selective sodium/iodide symporter (NIS). This sym-
porter is expressed mostly in the salivary glands, gastric tissues,
and thyroid gland.[2] Iodide is secreted in the saliva; it has been
suggested that this aids in maintaining the hygiene of the oral
cavity and acts as a salvage mechanism to recycle iodide when
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ments in the biostability and conclude with general guidelines
for the design of stable radioiodinated pharmaceuticals. It ap-
pears to be necessary to consider the whole molecule, rather
than the radioiodinated fragment alone. Iodine radionuclides
are generally retained in vivo on sp2 carbon atoms in iodo-
arenes and iodovinyl moieties, but not in iodinated hetero-
cycles or on sp3 carbon atoms. Iodoarene substituents also have
an influence, with increased in vivo deiodination in the cases
of iodophenols and iodoanilines, whereas methoxylation and
difluorination improve biostability.
the diet is deficient in iodine.[3] In the stomach iodide is be-
lieved to have a role in regulating the gastric pH.[4] Whereas it is
taken up in the tissues mentioned above, there is also empirical
evidence that iodide can actively be eliminated from the brain
across the blood-brain barrier (BBB) through a poorly under-
stood mechanism.[5]
The thyroid gland is very efficient, much more so than the
salivary glands and stomach, in clearing plasma of iodide. Iod-
ide avidly accumulates to allow the synthesis of thyroid hor-
mones (THs) T4 and T3 (Scheme 1). After uptake, through the
action of the NIS, across the basolateral membrane of the
thyrocyte, iodide is extruded across the apical membrane into
the thyroid gland's follicle lumen. Here, iodide is oxidized to
iodonium by thyroperoxidase (TPO) enzymes and mono- and
disubstituted on the phenolic rings of the accessible fraction of
the 137 tyrosine residues present in the glycoprotein thyro-
globulin (a process known as “iodide organification”). Next,
some of the iodinated phenolic rings (those with favorable spa-
tial disposition; namely, hormonogenic residues) are coupled,
with the terminal hydroxy group from one 3,5-diiodotyrosine
(DIT) residue attacking the ipso-carbon atom either of another
DIT residue or of a 3-iodotyrosine (MIT) residue. After endocyto-
sis of the luminal colloid contents, proteolysis of the oxidized
thyroglobulin will result in the production of THs (a mixture of
T4 and a small amount of T3) together with their intermediate
unreacted byproducts MIT and DIT. Iodothyronines are then re-
leased into the bloodstream, where they travel through the
body, mostly bound to carrier proteins.[6] Specific seleno-
cysteine-dependent (Sec-dependent) iodothyronine deiodin-
ases (DIOs, enzymes reviewed in Section 2) activate/deactivate
the THs by deiodination of the inner or the outer ring of the
iodothyronine molecule.[7]
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Scheme 1. Biosynthesis of iodothyronines.
The synthesis of THs is a rather inefficient process: Sorimachi
and co-workers found that each oxidized thyroglobulin, after
coupling between hormonogenic residues, affords – out of the
native 137 tyrosine residues – an average of six molecules of
MIT, six of DIT, three of T4, and one of T3.[8] The MIT and DIT
byproducts released after proteolysis are deiodinated by the
flavin-dependent iodotyrosine deiodinase (IYD, enzyme re-
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viewed in Section 2), so the excess iodine and the tyrosine moi-
eties can be salvaged.[9]
1.2. Iodine and the Brain
Other organs besides the thyroid gland can accumulate iodide,
including the brain. In particular, the mammalian choroid
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Scheme 2. Schematic representation of the deiodinating metabolism of (a) compound 1, and (b) compound 2.
plexus, a vascular network projecting into the brain's ventricles
and secreting the cerebrospinal fluid (CSF), can actively take up
and secrete iodide from and into the CSF.[10] Moreover, the BBB,
the highly selective epithelium that separates the brain from
the circulating blood, is a major pathway for uptake of iodide
into, and expulsion of iodide from, the brain.[11] These and
other early studies report that brain iodide transport is Na+-
dependent and perchlorate-sensitive,[11b,12] hinting at the in-
volvement of the sodium iodide symporter (NIS). However, no
NIS mRNA could be detected in human brain,[13] except in
breast cancer brain metastases.[14] Similarly, the other thyroid
iodide transporter, pendrin, could not be detected in human
brain,[15] leaving the exact iodide transport pathways in the
brain still to be determined.
The efflux of iodide from the brain, by whatever pathway,
has consequences for the development of radioiodinated phar-
maceuticals. Okamura et al.[12b] mimicked the efflux of iodide
liberated from a radioiodinated pentylpurine compound in
mouse brain. Elimination of 125I from the brain was virtually
complete after 20 min. The rapid loss of liberated iodide and
the retention of a radiolabeled probe will most likely enhance
the signal-to-noise ratio in, for instance, single-photon emission
computed tomography (SPECT) and positron emission tomog-
raphy (PET) applications.
Despite the fact that compound 1 (Scheme 2) showed
marked uptake of radioiodide in non-target organs outside the
brain (principally in the thyroid), it was successfully used to im-
age the uptake of 5-hydroxytryptamine in the brain.[16] Presum-
ably, uptake of compound 1 in the brain is faster than its de-
iodination. Compound 2 could not be used to image expression
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of cannabinoid receptors, due to nonspecific uptake in the
brain.[17] Presumably, the deiodination of compound 2 in the
brain and the efflux of radioiodide from the brain is much
slower than the deiodination of the tracer, resulting in accumu-
lation of nonspecifically localized radioiodide in the brain
(Scheme 2).
Strictly, in the development of a successful radioiodinated
tracer for a target located in the brain, if the deiodination rate
is slow enough to allow even a small proportion of the parent
compound to reach its target, the peripheral (outside the BBB)
deiodination might not affect the quality of the images. How-
ever, if the tracer is deiodinated in the brain, the iodide might
be expelled too slowly, resulting in a low signal-to-noise ratio
in the area of interest.
1.3. Iodine in Nuclear Medicine
A total of 37 isotopes of iodine are known, from 108I to 144I, of
which 127I is the only stable nuclide. Of the radioactive isotopes,
131I, 124I, and 123I find broad application in nuclear medicine,
whereas 125I is mostly used in biomedical research.
PET and SPECT are useful in vivo imaging techniques, allow-
ing target areas to be imaged with millimeter resolution, by
exploiting +- and γ-emission, respectively. In diagnostic nu-
clear medicine, a radioactive pharmaceutical (also called a
tracer), designed to accumulate selectively in target tissue, is
administered. The radioactive emissions of the tracer permit the
distribution of the compound in the body to be visualized
graphically. For instance, meta-iodobenzylguanidine (MIBG), a
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widely used radioiodinated pharmaceutical in both therapeutic
and diagnostic nuclear medicine, will accumulate selectively in
tissues rich in adrenergic receptors (e.g., tumors such as pheo-
chromocytomas and neuroblastomas). When using 123I-MIBG,
the γ-emissions of 123I are visualized with a γ-camera, allowing
delineation of the tumor. In therapeutic nuclear medicine, the
radioactive pharmaceutical will deliver the necessary radiation
dose to the target tissue, allowing the destruction of the tar-
geted tissue. For instance, when 131I-MIBG is administered, the
–-emissions of 131I will cause breaks in the DNA double strands
and will destroy the tumor tissue. 123I is the most widely used
iodine radionuclide for SPECT imaging because of the superior
physical characteristics of its emissions (159 keV, t1/2 = 13.3 h).
125I is most often used in research, to perform in vitro testing
in the development of radiopharmaceuticals or in displacement
assays of a radioactive ligand. It has also been used to perform
SPECT imaging, but – because its 35 keV emissions have a lim-
ited penetration range in tissues – it is only applied to small
animals. 131I has a powerful –-emission (971 keV) that can be
used for therapy and a 364 keV γ-emission for imaging. 124I is
a positron-emitting radionuclide (+ 603 keV) with a half-life of
4.2 d. It is mainly used as an alternative to 123I for imaging
studies with radioiodinated pharmaceuticals by PET instead of
SPECT (Table 1).[18]
Table 1. Selected iodine isotopes used in nuclear medicine. EC = electron
capture.
Nuclide t1/2 Decay Main emission Use in nuclear medicine
[keV]
131I 8 d – 364 SPECT
γ 971 therapy
125I 59 d EC 35.5 research
124I 4.2 d + and EC 603 (511) PET
123I 13.22 h EC 159 SPECT
The main drawback of radioiodinated pharmaceuticals is the
low in vivo stability of the C–I bond. Dissociation of the radio-
nuclide from the tracer results in unwanted accumulation of
iodine radioactivity in the thyroid, stomach, and salivary glands.
This will reduce the target-to-background ratio of the images.
In therapeutic nuclear medicine, non-target accumulation of
iodine radioactivity will reduce the radiation dose to the target
tissue and enhance the dose to non-target tissues. Hence, in
the design of radiopharmaceuticals, it is crucial to understand
the metabolic transformations that they are likely to undergo
in order to prevent or minimize deiodination.
1.4. Organic Iodides and Metabolic Transformations
Although much is known about the metabolism of endogenous
organic iodides, far less is known about the metabolic fate of
xenobiotics bearing this halide. Before analyzing the metabolic
transformations that a radioiodinated pharmaceutical could un-
dergo, it is important to understand the physicochemical prop-
erties of the C–I bond. The van der Waals radius of the iodine
atom (as shown in Table 2) is comparable with that of a methyl
group. It is substantially less electronegative than the other
smaller halogens, with a value comparable with that of carbon.
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Table 2. van der Waals radii[19] and electronegativities[20] for selected atoms/
groups.
C H F Cl Br I CH3
van der Waals radius [Å] 1.70 1.20 1.35 1.80 1.95 2.15 2.00
Electronegativity 2.50 2.28 3.98 3.03 2.80 2.47 2.30
The C–I bond is weaker than those between carbon and the
smaller halogens; this is considered to be due to the fact that
the orbital overlap between carbon and iodine atoms is less
efficient, resulting from the larger size of the iodine atom rela-
tive to that of the carbon atom. As can be seen in Table 3, the
bond dissociation energy (BDE) varies according to the hybridi-
zation state of the carbon atom to which the iodine atom is
attached: covalent binding to an sp2 carbon atom will result in
a stronger interaction than that to an sp3 or sp carbon atom.
In fact, the p orbital of the sp2 carbon atom can conjugate with
the outer electron shells of the halogen atom, stabilizing the
binding through resonance. Benzylic and allylic positions, how-
ever, show lower homolytic BDEs than other sp3 carbon atoms,
because the radicals generated from the dissociation of the hal-
ide are stabilized by their structural and electronic features.
Thus, the BDE is an important factor to be considered when
designating the iodination site in the synthesis of a new radio-
pharmaceutical; it is, however, not the only important variable.
Table 3. BDEs[21] calculated from Born–Haber thermodynamic cycles.
R–I Homolytic BDE Heterolytic BDE
[kJ mol–1] [kJ mol–1]
CH3–I 234.72 889.52
C2H5–I 222.59 722.58
(CH3)2CH–I 222.17 628.48
(CH3)3C–I 210.87 562.33
CH2=CHCH2–I 184.51 671.95
CH≡C–I 206.27 748.10
C6H5CH2–I 167.36 566.93
It is important also to consider the concept of the σ-hole,
which is described as a positive region found in calculations of
the electrostatic surface potential (ESP) areas of covalently
bonded atoms of groups IV–VII. In the case of iodine, such a σ-
hole is located coaxially to the C–I bond (red in Scheme 3). The
σ-hole is the result of the anisotropy of the ESP of the halogen
atom. This anisotropic model of the ESP was proposed in the
last decade to explain the experimentally observed halogen
bond (blue in Scheme 3) through a more coherent model than
the London forces.[22] The magnitude of the σ-hole may affect
the reactivity of organic halides: in fact, the halogen may form
a halogen bond with a Lewis base in vivo, potentially weaken-
ing the C–I bond. An example of such an in vivo deiodination
Scheme 3. Schematic representation of the σ-hole (red) of an organic (R =
any hydrocarbon moiety) iodide and its interaction (halogen bond, blue
dashed line) with a Lewis base (B).
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Scheme 4. Inner- and outer-ring dehalogenations catalyzed by the three DIOs.
Scheme 5. (a) Binding interactions between T3 and DIO3. (b) Reaction mechanism for IRD of DIO3. (c) Intramolecular recycling of the Sec residue, as proposed
by Schweizer and co-workers.[30]
mechanism is the inner-ring deiodination (IRD; Schemes 4 and
5b) of T4 or T3 by iodothyronine deiodinase 3 (DIO3), which is
thoroughly reviewed in Subsection 2.2. The magnitude of the
σ-hole on the iodine atom may be exploited as a computed
parameter to predict whether a given iodinated pharmaceutical
will undergo in vivo deiodination. A higher magnitude of the
σ-hole will result in stronger halogen bonding with a Lewis
base,[23,24] possibly weakening the C–I bond.
Kolàř and co-workers calculated the magnitudes for some
simple organic iodides; their results are summarized in Fig-
ure 1.[24] There is a slight increase in magnitude of the σ-hole
on iodine when bound to an sp2 (CH2CH–I and C6H5–I) rather
than to an sp3 (CH3–I) carbon atom. A twofold increase is ob-
served when iodine is bound to an sp (CH≡C–I) rather than to
an sp3 (CH3–I) carbon atom. The magnitude of the σ-hole on
the iodine atom in an iodoarene is markedly affected by the
nature and positions of the substituents. For instance, the mag-
nitude of the σ-hole on the iodine atom of iodobenzene (C6H5–
I) is doubled upon substitution of its hydrogen atoms by the
more electronegative fluorine atom (C6F5–I), it increases upon
substitution with electron-withdrawing groups (EWGs, e.g.,
nitro, CN, ...) and decreases upon substitution with more
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strongly electron-donating groups (EDGs, e.g., methyl, methoxy,
...). The magnitude of the σ-hole generally increases on iodine
in iodoheteroaromatic systems, such as 5-iodopyrimidine and
4-iodopyridine, but, interestingly, decreases for 2-iodopirim-
idine. For the design of radioiodinated pharmaceuticals it may
be useful to calculate the magnitude of the σ-hole in the chemi-
Figure 1. Magnitude [expressed in vmax/a.u. (maximum magnitude/atomic
unit)] of the σ-hole on iodine in selected iodinated organic molecules, as
calculated by Kolàř and co-workers.[24]
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cal environment of interest in silico. As can be observed
through this review, when radioiodine is installed on a more
electron-rich arene, the resulting iodinated radiopharmaceutical
is observed to undergo less deiodination, so a value of
0.027 vmax/a.u. (magnitude of the σ-hole of iodobenzene) could
be taken as a threshold as the maximum magnitude of the σ-
hole to prevent deiodination of an iodinated radiopharmaceuti-
cal. However, the composition and the structure of the whole
molecule, rather than just of the radioiodination site, will affect
the kinetics of the deiodination reaction: for instance, com-
pound 3 (Figure 2) is known to be biologically not stable,
whereas its homologue 4, in which the methylene group at C4
is substituted with an oxygen atom, was found to be stable in
vivo.[25]
Figure 2. 6-Iodohexanoic acid and its biologically stable homologue.
To understand this behavior, it is necessary to understand
the metabolic pathways a radioiodinated pharmaceutical might
undergo. If the iodinated pharmaceutical of interest is known
to be stable in an aqueous solution under standard conditions,
it is likely that dehalogenation is a result either of some interac-
tion with metabolic enzymes (deiodinases, formation of dehalo-
genating metabolites or nucleophilic enzymes) or of physical/
chemical decomposition in vivo. In fact, organic iodides can
often undergo physical/chemical decomposition. Thyroxine, for
instance, is already known to deiodinate in vitro in aqueous
solution, upon UV irradiation, or in a pH- and temperature-
dependent manner.[26] Thus, when assessing the metabolic sta-
bility of an iodinated pharmaceutical, it is crucial not only to
analyze the carbon–iodine BDE, but also to understand how the
whole molecule might interact with any metabolic pathway in
vivo.
In the next chapter, the enzymes that may catalyze deiodin-
ation are reviewed. Where possible, an in vitro test specific to
each enzyme category is given; this may help to provide insight
into the in vivo stability of a new radiopharmaceutical entity.
Afterwards, the in vivo behavior of some selected radio-
iodinated pharmaceuticals is illustrated in terms of biodistribu-
tion data, obtained from previously published patents and
peer-reviewed literature. Finally, an attempt is made to correlate
the metabolic dehalogenation rates of such pharmaceuticals
with their structures and to determine, which structural features
may hamper or favor metabolic deiodination.
2. Metabolic Pathways Leading to
Deiodination
It is important to identify the enzymes and cofactors involved
in the in vivo deiodination to estimate whether a new radio-
pharmaceutical entity, untested in vivo, will be biologically sta-
ble towards the loss of its iodine radionuclide. This section out-
lines the principal metabolic pathways that a radioiodinated
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pharmaceutical may undergo. After a discussion of the in vivo
mechanisms of the different dehalogenation reactions (in terms
of amino acids in the active sites of the enzymes involved or
cofactors), some “enzyme-free” testing methods for each spe-
cific pathway are presented.
2.1. Overview
Three main groups of enzymes that interact with radioiodinated
pharmaceuticals can be identified:
1. Deiodinases, which specifically catalyze the reductive
deiodination of an iodinated aromatic ring, often an ortho-iodo-
phenol.
2. Cytochrome P450 (CYP450) enzymes, which constitute the
main class of enzymes responsible for the oxidation of xeno-
biotics in vertebrates.
3. Nucleophilic nonspecific enzymes, which may attack a par-
ticularly electrophilic carbon atom, as on a particularly strongly
activated iodinated aromatic ring.
2.2. Deiodinases
Only two classes of mammalian deiodinases are known: iodo-
thyronine deiodinases (DIOs) and iodotyrosine deiodinases
(IYDs). Involved in the synthesis and regulation of thyroid hor-
mones, they differ slightly in their target substrates (thyroid hor-
mones and thyroid hormone byproducts, respectively), but
drastically in their deiodination mechanisms.
Iodothyronine Deiodinases (DIOs)
DIOs are Sec-dependent membrane proteins that catalyze the
reductive elimination of iodide from iodothyronines (thyroid
hormones). They are responsible for the activation and inactiva-
tion of thyroid hormone signaling (Scheme 4). T4 represents
most of the circulating thyroid hormone and travels through
the body bound to its specific protein carrier. It is a pro-hor-
mone, the activated form of which – T3 – binds to specific
nuclear receptors that trigger signaling cascades leading to
gene activation and consequent protein synthesis, accelerating
cellular metabolism and other physiological processes, such as
thermogenesis and lipolysis. rT3 and T2 are inactivated forms
of the thyroid hormones, characterized by the loss of the iodine
atom from the inner ring. DIOs regulate the homeostasis of the
thyroid hormones, and they exist in three isoforms. They differ
in kinetics, substrate, and location in the organism. The amino
acid sequence in the active site is, however, highly conserved.
Their principal characteristics are shown in Table 4.
DIO1 catalyzes both outer-ring deiodination (ORD) and in-
ner-ring deiodination (IRD), and it shows the highest affinity for
rT3, in vitro, suggesting a scavenging role for this enzyme in
the metabolism of thyroid hormones. Nevertheless, its activity
is believed to contribute to a significant portion of the circulat-
ing T3. It is strongly inhibited by propylthiouracil (PTU; Fig-
ure 3), iodoacetate, and gold thioglucose (GTG). DIO2 is the
main enzyme involved in thyroid hormone activation, catalyz-
ing the ORD of T4 and generating T3. It is indeed responsible
for most of the T3 produced in the brain. Amiodarone is a se-
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Table 4. Characteristics of the different isoforms of DIOs.
Location Substrate preference Michaelis–Menten constant order
DIO1 liver, kidney, thyroid rT3 (ORD) > T4 (IRD) μM
DIO2 brain, placenta, thyroid, skeletal muscle, heart T4 (ORD) > rT3 (ORD) nM
DIO3 brain, placenta, pregnant uterus, fetal tissues T3 (IRD) > T4 (IRD) μM
lective inhibitor for DIO2, but its pleiotropic effects and targets
preclude its use for study of DIO2 in vivo.[27] DIO3 has a protec-
tive role: through the inner-ring deiodination (IRD) of T3 it ter-
minates the thyroid hormone signaling and prevents its overac-
tivation, especially during fetal growth. DIO2 and DIO3 are
strongly inhibited only by GTG and iopanoic acid, which are
nonselective DIO inhibitors.[28,29]
Figure 3. Selected known DIO inhibitors.
In 2014, the group of Schweizer and co-workers[30] solved
the crystallographic structure of DIO3, unveiling its unique
mechanism. Figure 4 shows a schematic view of its organiza-
tion: it is a selenoprotein that shares most of its structure with
the thioredoxin-fold (Trx-fold) protein (cyan in Figure 4). It also
contains a peroxiredoxin-like (Prx-like) module (purple in Fig-
ure 4) and a lid (blue in Figure 4), which, by covering the sub-
strate, is partially responsible for substrate recognition. Most of
the catalytic residues are located in the Trx-fold domain, on top
of the α-motif. The main difference from the native Trx-fold
protein lies in the substitution in DIO3 of a cysteine residue by
a Sec one. The protein is activated through homodimerization,
displacing a phenylalanine residue that would instead occupy
the catalytic cleft. His202, from the DIO-insertion domain, acts
as a binding partner, tethering the 4′-phenolic end of the sub-
strate, whereas the zwitterionic terminus interacts favorably
with the carboxylate group of Glu215 and the guanidinum
group of Arg275, allowing T3 to lie in the catalytic cleft
(Scheme 5a). From the top side of the substrate, the selenide,
formed by deprotonation of the Sec170 residue by a nearby His
residue (not shown), behaves as a Lewis base and attacks the
σ-hole of the iodine, forming a halogen bond (Scheme 5b, red
dashed line). The thiol group of Cys239 interacts with the selen-
ium through chalcogen-bonding (Scheme 5b, purple dashed
line) to facilitate the cleavage of the C–I bond, inducing the
transfer of electron density to its σ* orbital. The iodine atom is
replaced with a proton approaching from the bottom side of
the ring, conveyed by the triad of residues Ser167, Glu200, and
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His219 (Scheme 5b, blue arrow). This complex H-bond network
is further sustained by Tyr197 and Thr168. Although it was first
believed that the nearby Cys168 residue was crucial in the cata-
lytic reaction,[31] the structure determined by Schweizer and co-
workers showed that in the reduced form of DIO3 this residue
has its side chain pointing outwards from the catalytic cleft.
When oxidized, DIO3 uses this thiol moiety to regenerate the
selenyl residue. The selenol is restored by isomerization of the
selenyl-sulfide Sec170–Cys239 (purple in Scheme 5c) to the disulf-
ide Cys168–Cys239 (red in Scheme 5c). The model of deiodination
by DIO3 described above and shown in Scheme 5 is supported
by theoretical density functional studies by Bayse and co-work-
ers,[32] mechanistic studies by Manna and co-workers,[33] and
the crystal structure by Schweizer and co-workers.[30]
Figure 4. Schematic view of DIO3 tertiary structure. Catalytically important
residues are shown. Reproduced from ref.[30] (Crystal structure of mammalian
selenocysteine-dependent iodothyronine deiodinase suggests a peroxiredoxin-
like catalytic mechanism: U. Schweizer, C. Schlicker, D. Braun, J. Kohrle, C.
Steegborn, Proc. Natl. Acad. Sci. USA 2014, 111, 10526–10531), with permis-
sion from the Proceedings of the National Academy of Science.
In trying to understand the catalytic mechanism of this en-
zyme, Manna and co-workers[31] developed a simple selenyl-
dependent chemical system, mimicking the reaction occurring
at the catalytic cleft of DIO3 (Scheme 6). Compound 5 should
act as the Sec170–Cys239 couple in DIO3, bearing both the
selenol residue, to attack the iodine, and the proximal thiol
group, to facilitate the cleavage of the C–I bond. In their experi-
ments, they treated T4 with compound 5 under physiological
conditions, achieving rT3 in high yield and recovering 6, the
oxidized form of 5. This very simple assay, although it does not
take the substrate selectivity of the enzymes into account, may
be deployed to test the metabolic stability of an iodinated
pharmaceutical towards IRD by DIO1 or DIO3 enzymes. Despite
the bulk of experimental data, there is no coherent answer to
the mechanism of ORD by DIO2. The homology of the catalyti-
cally relevant amino acids over the three types of DIO would
seem to suggest a similar mechanism, as proposed by
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Scheme 6. System engineered by Manna and co-workers to mimic IRD.[31]
Scheme 7. (a) Proposed docking of T4 in the DIO2 catalytic cleft (Callecaut and co-workers).[34] (b) Proposed reaction mechanism for DIO2 deiodination
passing through a tautomeric intermediate. (c) Chemical system developed by Goto and co-workers to mimic the Sec-dependent dehalogenation.[35]
Schweizer and co-workers. However, the replacement in the cat-
alytic cleft of Arg275 for a lysine residue in DIO2 causes confor-
mational changes in the binding site, which opened up the
possibility that the substrate might lie in a reversed position
(Scheme 7a). This docking position would still allow the Sec
residue to adopt a favorable position to attack the iodine.[34] It
is unclear whether this mechanism proceeds via a tautomeric
intermediate (Scheme 7b) or is induced by chalcogen bonding.
While studying molecular cavities capable of stabilizing the
selenyl iodide functionality, Goto et al. developed a reagent
bearing a selenyl group capable of mimicking the reaction oc-
curring at the Sec residue and also of stabilizing the formation
of a BpqSeI adduct (Scheme 7c).[35] In this dehalogenation proc-
ess, a protected derivative of T4 – compound 7 – is heated in
chloroform for 1 week, in the presence of BpqSeH, to yield the
T3 homologue 8. Although the conditions described by Goto
are far from physiological, this reaction might be used in the
future to develop methods to test the stability of a given
iodinated pharmaceutical towards ORD by DIO2.
Iodotyrosine Deiodinase (IYD)
IYD, found in the thyroid gland, is a flavin-dependent oxido-
reductase of the NADH oxidase/flavin reductase superfamily. It
was crystallized in 2009 (Figure 5), bound to the reductive pros-
thetic group flavin mononucleotide (FMN; Figure 5 in cyan; see
also Figure 6) and 3-iodotyrosine (MIT).[9] The active site is char-
acterized by an α-helix (green in Figure 5) constituting a lid that
envelops the MIT substrate and the FMN group. The side chains
from the lid are engaged in important binding interactions with
the MIT substrate (Figure 5a), whereas the FMN is bound to
more buried amino acids.
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Figure 5. (a) Relevant interactions in the active site between IYD and MIT.
Lateral chains from the lid interacting with MIT are highlighted in green, MIT
in yellow, and the FMN prosthetic group in cyan. (b) Overall view of IYD with
its substrate bound. The lid is highlighted in green, MIT in yellow, and the
FMN prosthetic group in cyan. Adapted from Thomas et al. pdb ID: 3gfd.[9]
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Figure 6. Flavin mononucleotide (FMN) and N-methylpyrimidone.
Binding between MIT and FMN is mediated by the 2′-
hydroxy group of FMN (red in Figure 6), which binds to the
phenolic end of the substrate. This interaction is very important
for substrate recognition; in fact, structure–activity relationship
(SAR) studies conducted by McTamney and co-workers revealed
that substitution on the phenolic ring, increasing the pKa of the
phenol, resulted in improved binding.[36] The same group also
discovered that IYD is strongly inhibited by tyrosyl analogue 9
(Figure 6). Increasing or reducing the size of the N-alkyl substit-
uent resulted in reduced inhibition, showing a specific recogni-
tion site for an ortho substituent with the specific size of iod-
ine.[37] The mechanism of dehalogenation by IYD is quite
unique in vertebrates, and only very recently, after having
solved its crystal structure, did the group of Rokita propose two
plausible possibilities (Scheme 8a and b).[38] For the first, they
proposed tautomerism as the driving force with FMN acting as
a reducing agent (Scheme 8a). The second proposed mecha-
nism (Scheme 8b) instead envisaged a single-electron transfer
to activate the iodinated phenolic ring, resulting in the reduc-
tive elimination of iodide. Both mechanisms have precedent in
biochemistry, and further studies will be needed to understand
the actual catalytic mechanism of this exotic enzyme. Rein-
wein's group described an in vitro deiodinating system involv-
ing T4 and FMN under physiological conditions (Scheme 11c,
Scheme 8. (a), (b) Proposed mechanisms for reductive dehalogenation by IYD (Rokita and co-workers).[38] (c) Non-enzymatic deiodination as described by
Reinwein and co-workers.[39]
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below).[39] The substrate is slightly different from MIT or DIT;
however, because the catalyzed reaction is similar (ORD of T4,
in comparison with iodotyrosine deiodination), we would ex-
pect the mechanism to be similar too. In this system, FMN is
added to a solution of T4 in phosphate buffer, while the reac-
tion mixture is exposed to light. Total deiodination of T4 is usu-
ally observed in 15 min. This system may be deployed to test
in vitro whether a new radioiodinated compound is stable or
not towards IYD.
2.3. Oxidative Deiodination by CYP450
The cytochrome P450 (CYP450) family, expressed mostly in the
liver and the lungs, represents the most important class of met-
abolic enzymes in aerobic organisms. It catalyzes the oxidation
of xenobiotics in order to increase their hydrophilicity, thus fa-
cilitating their clearance from the blood and their consequent
excretion in the urine as hydrophilic metabolites. The metabolic
oxidation of iodinated hydrocarbons may lead to deiodination.
In the following subsections we review the known oxidative
deiodination of selected iodinated structural features. Finally,
some considerations relating to the selectivity of CYP450 en-
zymes, which might be useful in the design of radioiodinated
pharmaceuticals, are reported.
Iodoanilines
Cnubben's group described the concomitant deiodination of
para-iodoanilines such as 10 upon oxidation in the presence of
CYP450 enzymes (Scheme 9).[40] Oxidation to the aminoquin-
one derivative 11 by NADPH/O2 in the presence of CYP450 re-
sults in loss of iodide and insertion of an oxygen atom. Further
reduction by NAD(P)H gives the deiodinated adduct 12, in
which the position previously occupied by iodine is oxidized to
OH. This reaction has been observed to occur only in the case
of para-iodoaniline derivatives activated by a halogen in the
ortho position to the amine group.
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Scheme 9. Reaction pathway proposed by Cnubben and co-workers for the
CYP450-catalyzed dehalogenation of 4-halogenated anilines. X = halogen
atom.[40]
Aliphatic Iodides
Tachizawa and co-workers proposed that CYP450 enzymes were
responsible for the dehalogenation of terminal alkyl halides
such as 13. They observed that the most important reaction
catalyzed by this enzyme family on substrates of this kind is the
hydroxylation of the halogenated carbon atom (Scheme 10),
resulting in a very unstable α-hydroxy halide of type 14, which
would quickly lose the halogen, yielding the corresponding
aldehyde 15.[41]
Scheme 10. Deiodination mechanism based on hydroxylation as proposed by
Tachizawa and co-workers.[41]
Vinyl Iodides
According to Guengerich and co-workers, CYP450 would also
oxidize vinyl iodides such as 16 to their corresponding epoxides
17 (Scheme 11).[42] Epoxide hydrolase was then found to be
responsible for the opening of the epoxide to glyoxaldehyde
(18), with consequent loss of iodide. Alcohol dehydrogenase
(ADH) would instead open the epoxide and oxidize the result-
ing iodoethanol derivative to iodoacetaldehyde (19), without
loss of iodide.
Scheme 11. Oxidation of vinyl iodide as proposed by Guengerich and co-
workers.[42]
Selectivity of CYP450 Enzymes
Despite the metabolic transformation described immediately
above, a vinyl moiety is often chosen as a radioiodination site
because of the high bond dissociation energy (BDE) of an sp2
carbon atom bound to an iodine atom (Table 3). The formation
of deiodinating metabolites by CYP450 enzymes may be
avoided by decreasing the lipophilicity of the whole molecule.
For instance, Neto and co-workers designed and synthesized
the estradiol analogues 20a and 20b, differing in the nature of
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the R substituent (Figure 7).[43] As can be seen from Table 5,
compound 20b (bearing a nitrile in place of an amide) is de-
iodinated much more rapidly than 20a, with a very high resid-
ual radioactivity in the thyroid even 24 h after administration.
To explain this result, it is necessary to understand how differ-
ently these two molecules will interact with their metabolic
agent, CYP450. The main role of CYP450 enzymes is to catalyze
the metabolism of xenobiotics to more polar (thus more hydro-
philic) derivatives that can be excreted easily through the kid-
neys. Compound 20a (bearing a terminal amide group) is more
polar (C log P = 5.6 vs. 6.4) than 20b, and then already more
hydrophilic. Compound 20b, being more hydrophobic than
20a, needs to be further oxidized by CYP450 to be efficiently
excreted, resulting in more loss of radionuclide.
Figure 7. Estradiol analogues designed and synthesized by Neto and co-work-
ers.[43]
Table 5. Radioactivity accumulation in rat thyroid as % ID/g organ and C log P
for 20a and 20b (n = 4–5); ID = injected dose; C = computed; P = partition
coefficient; n = number of experiments for each time point.
C log P 1 h 2 h 24 h Ref.
20a 5.6 0.29 ± 0.07 0.49 ± 0.18 0.03 ± 0.01 [43]
20b 6.4 1.0 ± 0.2 0.9 ± 0.1 10.1 ± 3.1 [43]
With regard to the selectivity of CYP450, Cnubben et al.
showed that increasing the size of the halogen (red in Figure 8)
and the overall molecule results in reduced turnover rates of
the enzyme (X = F, apparent Vmax = 2.99; X = I, apparent Vmax =
0.29).[40] It appears that increasing the size of the molecule
hampers its access to the CYP450 catalytic site.
Figure 8. Compounds assayed by Cnubben against CYP450 oxidative dehalo-
genation.[40] X = halogen.
The CYP450 isoforms differ drastically in terms of substrate
selectivity and distribution in the body. The selectivity of
CYP450 isoforms has already been reviewed in a recent work
by Olsen and co-workers and goes beyond the scope of this
review.[44]
CYP450 enzymes may be inhibited by known CYP450 inhibi-
tors such as isonicotinic acid hydrazide[45] or fluconazole.[46] It
is important to mention that it is particularly difficult to mimic
a metabolic CYP450 system. For instance, Cnubben et al. in their
studies relied exclusively on in vitro testing, and their testing
mostly involved proteins purified ex vivo because of the intrin-
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sic difficulties of creating a CYP450 mimic system. Feiters and
co-workers reviewed the advances in obtaining CYP450 mimics;
however, they all require very bulky and expensive reagents
and often ad hoc supramolecular systems, required to simulate
the complexity of this class of enzymes.[47] The synthetic radio-
chemist, aiming to understand whether a radioiodinated phar-
maceutical may be a substrate for CYP450 enzymes, may use a
predicting software, in vitro incubation with tissue extracts, or
animal models, as reviewed by Kirchmair and co-workers.[48]
2.4. Nucleophilic Deiodination
In organic chemistry, iodine is also known to be an excellent
leaving group in nucleophilic substitution reactions, so we
would expect iodinated hydrocarbons to react with nucleo-
philic moieties, such as the thiol group in glutathione (GSH),
resulting in conjugated adducts and release of iodide in the
bloodstream. In addition, it is important to anticipate that
some aryl iodides may react with GSH after previous intermedi-
ate oxidation by CYP450, as can be seen in the next subsec-
tions.[50]
para-Iodonitrobenzenes/Iodoanilines
The first evidence of a GSH-dependent dehalogenation, occur-
ring in the human liver, was found by Sinsheimer and co-work-
ers.[49] Assuming no deiodinases were implied in this process,
Sinsheimer treated para-iodoaniline (21a) or para-iodonitro-
benzene (21b) with liver homogenates either enriched in, or
free of, GSH. He was able to observe that para-iodoaniline
(Scheme 12) was not significantly deiodinated, whereas para-
iodonitrobenzene could lose iodide, and that the rate of this
metabolic process was accelerated by the addition of GSH.
From his findings it is clear that an electron-withdrawing group
such as NO2 favors the conjugation of GSH, supporting a meta-
bolic model in which GSH is conjugated by nucleophilic addi-
tion.
Scheme 12. Results of the early studies by Sinsheimer and co-workers.[49]
ortho-Iodoanilines
Zhang and co-workers recently studied the metabolism of
ortho-iodoanilines and discovered that, after an initial oxidation,
ortho-iodoanilines of type 22 are conjugated with a GSH
molecule, resulting in the 2-deiodinated adducts 23
(Scheme 13).[51] Although para-iodoanilines are seemingly not
deiodinated through a GSH-dependent process (as seen in the
previous subsection), ortho-iodoanilines may undergo this
Eur. J. Org. Chem. 2017, 3387–3414 www.eurjoc.org © 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim3397
metabolic transformation due to the proximity of the iodinated
carbon atom to the reactive ipso-carbon atom.
Scheme 13. GSH-dependent dehalogenation as described by Zhang and co-
workers.[51] X = chlorine or bromine but not fluorine.
The actual mechanism of this metabolic reaction is rather
complex, but Zhang and co-workers proposed that it should
proceed through the ipso addition of GSH to 24, an oxidation
product of intermediate 22 (blue in Scheme 14) formed upon
initial oxidation by CYP450 enzymes. Next, the migration of the
glutathionyl (GS) group to the 2-position (concomitant with iod-
ide elimination) would restore the aromaticity, yielding the de-
halogenated adduct 23 conjugated to a glutathionyl molecule.
This metabolic pathway is easily detectable because of the pres-
ence of the GSH conjugate. Because the biological reaction is
complex, involving oxidation and GSH addition (at least two
enzymes), it is difficult to define a chemical system capable of
mimicking such a series of reactions, other than the use of liver
homogenates. For the same reason, no selective inhibitor of
this pathway can be defined.
Scheme 14. Mechanism proposed by Zhang and co-workers.[51]
2.5. Summary and Discussion
This section describes the metabolic pathways that may lead to
deiodination. For each pathway, the enzymes and the cofactors
involved are analyzed. When possible, some specific inhibitors
for each enzyme are proposed. Furthermore, for dehalogenase
enzymes, simple chemical systems able to replicate the reac-
tions happening at the active site are described. However, those
in vitro testing methods, although potentially able to avoid ex-
pensive in vivo assays, may be misleading. Thus, ex vivo testing
is often preferred; as described by Owens and co-workers, this
consists of TLC analysis of blood extracts after administration
of a non-radiolabeled analogue.[52] However, this latter form of
test is only qualitative, so the most effective assay to determine
the metabolic stability of a radioiodinated compound is the
radio-HPLC analysis of the ex vivo acetonitrile extracts of
plasma samples at different time points, as further described
by Owens and co-workers.[52]
Lastly, now that the crystal structures of mammalian de-
iodinases have recently been determined, the radiochemist may
perform docking studies of untested ligands on the crystal
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structures of the deiodinases, in order to predict whether a new
radiopharmaceutical entity may be a substrate for such en-
zymes. Unfortunately, to date, no such studies have yet been
published.
3. Structural Features Enhancing or
Hampering the in Vivo Deiodination of
Radioiodinated Pharmaceuticals
This section describes correlations between the structural fea-
tures of radioiodinated pharmaceuticals and their radionuclide
dissociation rates. In vivo deiodination has been assessed by
analyzing biodistribution data, generally expressed as residual
iodine radioactivity measured for each organ after euthanasia
of the animal, reported in research journals and patents.
The capability of any metabolic pathway (such as those ana-
lyzed in the previous section) to cleave a radionuclide is strictly
related to the whole structure. However, in the following sub-
sections a tentative correlation of iodinated structural features
(iodinated scaffolds common in medicinal chemistry) with their
deiodination rates is proposed. Furthermore, some examples of
rational drug design to avoid deiodination are given later in
this review.
3.1. Carbocyclic Aromatic Moieties
Iodotyramines
To obtain a stable tracer labeled with an iodine isotope, it is
generally considered in medicinal chemistry that ortho-phenolic
positions should be avoided because of similarity with the
outer ring of the thyroid hormones. In fact, there is good evi-
dence of enzymatic in vivo deiodination occurring specifically
on iodotyramine derivatives [i.e., derivatives of 4-(2-amino-
ethyl)-2-iodophenol (25), Figure 9]. The process is very likely
enzyme-catalyzed because of its intrinsic specificity: radio-
labeled MIT and compounds 25, 26, and 27 are quickly de-
iodinated (MIT more rapidly than 27),[53–55] whereas even 28
(exogenous radioactive enantiomer of MIT) is instead metaboli-
cally stable.[56] Minimal variations in the structure of MIT, such
as α- or O-methylation (compounds 29 or 30, respectively) also
result in almost complete retention of the radionuclide.[53] Tyr-
amine is the pharmacophore responsible for the binding of
opiates to μ-opioid receptors (MORs)[57] and is present in mor-
phine, the iodinated analogue 31 of which is reported to be
metabolically stable towards deiodination.[58] This behavior can
be explained in terms of the selectivity of the deiodinase en-
zyme: compound 31, being a complex natural product, has a
strained three-dimensional structure that likely does not fit the
catalytic cleft of the deiodinating enzyme. On the other hand,
compound 27 is metabolically not stable.[55] Its tyramine moi-
ety is embedded in a structure less strained than that in 31,
allowing the compound to adjust its three-dimensional struc-
ture to fit the catalytic cleft of the deiodinating enzyme.
Compounds 25 and 26, being simpler than MIT (which is the
endogenous substrate of iodotyrosine deiodinase, IYD), are
both substrates for enzymatic deiodination, and show the mini-
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mal structure (iodotyramine) necessary for binding to the meta-
bolic enzymes.
Figure 9. Selected compounds bearing radioiodine on a tyramine moiety
(highlighted in red).
Compound 32 (Figure 10) is only slightly deiodinated, with
decreasing radioactivity accumulation in the thyroid, reaching
a maximum value of 0.68 % after 15 min (ID/g, human sample,
thyroid blocked). Compound 33, up to 30 min p.i., is mostly
excreted as the native compound (>96 %, urine), with only 4 %
residual radioactivity resulting from free radioiodide.[59] Com-
pounds 32 and 33, although only positional isomers of MIT, are
more resistant to deiodination than the α-methyl counterpart
29. Analogue 29 may still be a substrate for deiodinases,
whereas 32 and 33 are not substrates at all, demonstrating fur-
thermore the selectivity of the enzyme(s) implicated in this par-
ticular deiodination process. Tyramine derivative 26 (Figure 9)
is the decarboxylated analogue of 32; its instability in relation
to 32 may be due to the lack of one anchor point (i.e., ionizable
moiety capable of strong electrostatic interaction with charged
moieties in biomolecules) that would allow the molecule to fit
better for its binding interactions within the binding cleft. It is
difficult to determine which deiodinase [one of the iodo-
thyronine deiodinases (DIOs) or iodotyrosine deiodinase (IYD)]
Figure 10. First row: selected compounds bearing radioiodine on a tyramine
moiety. Second row: compounds bearing radioiodine on a phenol moiety.
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is implied in this reductive deiodination process. However,
given the higher similarity of iodotyramines to iodotyrosine
than to iodothyronines, IYD may be the most likely enzyme
leading to their deiodination. Furthermore, iodotyramines lack
a second aromatic ring (present in thyroid hormones), and they
may fit the catalytic cleft in DIOs less efficiently than in IYD.
Iodophenols
Compounds 34 and 35 (Figure 10) are ortho-iodophenols and
are both assumed to be stable towards deiodination, showing
a very mild accumulation of iodine radioactivity in the thyroid
(for 34)[60] and in the stomach (only relevant data given for
35)[61] as shown in Table 6. However, further analysis performed
with 35 (Figure 11)[62] revealed that some deiodination could
occur, with a PET scan of an injected mouse showing some
uptake in the thyroid.
Figure 11. PET scan taken 1 h post injection (p.i.) of compound 35. Repro-
duced from ref.[62] (Synthesis and in vitro/vivo Evaluation of Iodine-123/124
Labelled Hypericin Derivatives: S. W. Kim, J. H. Park, S. D. Yang, M. G. Hur, C. W.
Choi, K. H. Yu, Bull. Korean Chem. Soc. 2008, 29, 2023–2025), with permission
from the Korean Chemical Society.
Rather than being enzymatically deiodinated, 35 is more
likely to lose the radionuclide due to secondary reactions with
oxidizing/reducing agents present in tissues because of its very
dense and bulky carbon core, which is not very likely to fit into
the active site of an enzyme evolved to fit an iodotyrosine or
an iodothyronine. Also, the iodinated ring is much more acti-
vated than in 34, with 35 being a planar, aromatic system made
up of eight unsaturated six-membered rings, thus making the
C–I bond more labile. Although not directly due to deiodinases,
the mild deiodination of iodohypericyn 35 might be a result of
tautomerism, which would facilitate nucleophilic attack on the
iodide by any thiol moiety.
Table 6. Accumulation of iodine radioactivity in selected organs for compounds 34–36.
Organ 2 min 10 min 15 min 0.5 h 1 h 4 h 6 h 24 h Ref.
34 stomach[a] n.a. n.a. 2.57 ± 1.92 2.38 ± 0.88 2.33 ± 0.17 1.82 ± 0.4 1.13 ± 0.27 0.12 ± 0.08 [60]
thyroid[a] n.a. n.a. 0.02 ± 0.01 0.02 ± 0 0.02 ± 0 0.05 ± 0.02 0.11 ± 0.05 0.41 ± 0.22 [60]
35 stomach[b] n.a. 0.4 ± 0 n.a. n.a. n.a. 0.9 ± 0.2 n.a. 0.8 ± 0.2 [61]
36 thyroid[c] 0.156 ± 0.005 n.a. 0.064 ±0.005 0.073 ± 0.015 0.087 ± 0.007 0.376 ± 0.016 n.a. 2.32 ± 0.25 [63]
[a] ID/g %, rats, n = 10. [b] ID/organ %, mice, n = 3. [c] ID/organ %, rats, n = 3.
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Compound 36 (Figure 12) is biologically incredibly stable,[63]
most likely due to the different positions of the OH and I groups
in relation to those in a native iodotyramine. Also, the halo-
genated aromatic ring contains a methoxy group, which, by
donating electron density through resonance, is likely to stabi-
lize the C–I bond.
Figure 12. Selected compounds bearing radioiodine on an ortho-iodophenol
moiety.
On the other hand, the endothelin receptor imaging agent
37 could not be applied successfully because of nonspecific
accumulation in the liver and in the plasma.[64] Although no
metabolic data are given, nor data relating to any eventual ac-
cumulation in the thyroid, this result likely reflects two meta-
bolic processes: glucorinidation (accounting for the accumula-
tion in the liver) and deiodination (likely resulting in high
plasma accumulation). In addition, the metabolites produced
by the fragmentation of compound 37 may become good sub-
strates for deiodinase enzymes.
Iodoanilines
Aniline is a common scaffold in medicinal chemistry. It is often
chosen for radioiodination, being particularly activated towards
electrophilic substitution. However, as was shown in the previ-
ous section, iodoanilines are a class of substrate for CYP450
metabolic transformations (especially para-iodoanilines) and/or
GSH addition (especially ortho-iodoanilines), resulting in loss of
the radionuclide. Most pharmaceuticals incorporating iodo-
aniline have the iodo substituent in the meta position (Fig-
ure 13). Nevertheless, this particular molecular scaffold is always
prone to deiodination. This behavior may be explained in terms
of the capability of the aniline moiety to be partially protonated
in vivo: the positively charged substituent on the aromatic ring
will decrease the C–I bond dissociation energy (BDE) and widen
the σ-hole on the iodine, making the molecule more prone to
deiodination. In fact, in vivo pharmacokinetic studies of com-
pound 38 (Figure 13), bearing a guanidine substituent (largely
protonated under physiological conditions), showed the radio-
nuclide to be completely lost in ca. 5 min p.i. (t1/2 =
2.17 min).[52] Compound 39 (Figure 13) is more stable than 38,
but it is still significantly deiodinated in vivo, already showing
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Table 7. Accumulation of iodine radioactivity for compounds 39–42.
5 min 15 min 0.5 h 1 h 2 h 4 h 6 h 12 h 24 h Ref.
39[a] 2.79 ± 0.59 16.04 ± 1.86 21.18 ± 4.05 28.62 ± 5.33 16.31 ± 2.10 n.a. 15.28 ± 2.48 n.a. n.a. [65]
40[b] 0.10 ± 0.02 n.a. 0.15 ± 0.04 0.41 ± 0.11 0.96 ± 0.06 2.34 ± 0.06 2.68 ± 0.66 5.15 ± 1.49 4.61 ± 1.21 [66]
41[c] 0.08 ± 0.03 n.a. 0.13 ± 0.002 0.22 ± 0.08 0.63 ± 0.20 1.28 ± 0.67 1.31 ± 0.21 n.a. n.a. [67]
42[d] 0.08 ± 0.02 n.a. 0.04 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.04 ± 0.04 n.a. n.a. n.a. [68]
[a] Stomach, ID/g %, mice, n = 4. [b] Thyroid, ID/organ %, rats, n = 3. [c] Thyroid, ID/organ %, rats, n = 3. [d] Thyroid, ID/organ %, rats, n = 3.
a very low target-to-background signal at 1 h p.i., as found by
Hirata and co-workers.[65] Although the biodistribution data
(Table 7) for compound 39 cannot be directly compared with
those for 40–42 (Figure 13),[66–68] because no thyroid data are
given for 39 and the experiments were conducted on different
species, there is evidence for compound 40 being less prone to
deiodination than 39. Interestingly, adding an electron-donat-
ing substituent (O/SAr in 40 and 41) to the meta-iodoaniline
moiety results in increased biostability of the scaffold. More-
over, the replacement of the oxygen atom in 40 with sulfur in
41 leads to a more stable analogue. In fact, the outer electrons
of sulfur, because of its reduced electronegativity relative to
oxygen, are more available to be donated through resonance,
making the substituent even more electron-donating. Most
likely, electron-donating substituents increase the biostability
of iodoanilines. Interestingly, compound 42, not containing an
aniline moiety, with the nitrogen substituted with a CH2OH
group, proved to be metabolically completely stable, showing
zero accumulation of iodine radioactivity in the thyroid. This
comparative result would further support the hypothesis that
Figure 13. Selected compounds bearing radioiodine on an aniline derivative
moiety.
Table 8. Accumulation of iodine radioactivity in the stomach (mice) for compounds 39, 43, and 44. Data are given as ID/g %, n = 3.
5 min 15 min 0.5 h 1 h 2 h 3 h 6 h Ref.
39 2.79 ± 0.59 16.04 ± 1.86 21.18 ± 4.05 28.62 ± 5.33 16.31 ± 2.10 19.85 ± 2.80 15.28 ± 2.48 [69]
43 2.08 ± 0.43 7.88 ± 2.38 5.06 ± 2.59 3.56 ± 0.89 6.85 ± 0.13 5.20 ± 1.05 8.39 ± 1.13 [69]
44 1.60 ± 0.27 4.00 ± 0.64 4.70 ± 0.60 3.05 ± 0.72 3.65 ± 1.14 3.71 ± 0.54 3.89 ± 1.03 [69]
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anilines are not a biologically particularly stable group for radio-
iodination.
Anilines – Drug Design Strategy Example
In their efforts to obtain radioiodinated EGFR-TK imaging
agents, Hirata and co-workers synthesized the analogues de-
picted in Figure 14 [69] After they observed that the first ana-
logue they obtained – 39 – deiodinated rapidly in vivo (see
Table 8; the high accumulation of iodine radioactivity in the
stomach already after 15 min p.i.), they proceeded by trying to
modify the spacer between the quinazoline ring and the iod-
inated moiety. Firstly, from an iodoaniline they switched to an
iodophenoxy moiety, yielding compound 43, which displayed
a more than fourfold increase in biostability. In another ana-
logue – 44 – they inserted a one-carbon spacer between the
nitrogen atom and the aromatic iodinated moiety, giving a
compound twice as biostable as 43. In vivo protonation of the
quinazoline ring is likely to activate the iodoaromatic moiety
towards dehalogenating metabolism. This effect is more pro-
nounced when the linker is a nitrogen atom than when it is a
carbon or oxygen atom.
Figure 14. EGFR TK imaging agent candidates.
Iodoarenes
In medicinal chemistry, it is commonly assumed that aryl moie-
ties are good sites for radioiodination,[73] firstly due to the ease
of attachment of the radionuclide to such fragments, and sec-
ondly due to the high energy of the thus-formed Ar–I bond. In
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the following subsection some successful radioiodinated phar-
maceuticals bearing the radionuclide on simple arenes are re-
viewed and compared with other compounds radioiodinated in
different positions as discussed in previous subsections. Next, it
is discussed how the relative position of iodine (ortho/meta/
para) and different substituents may affect the deiodination
rates.
Compound 45 (Figure 15), patented by the Julius Maximili-
ans University of Würzburg, was stable in mice, displaying accu-
mulation of iodine radioactivity below 5 % (ID/g) until 4 h
p.i.,[74] thus demonstrating that iodoarenes are biologically gen-
erally stable. Compound 46 is an analogue very similar to com-
pound 27 (Figure 9), in which the radionuclide was shifted to
the non-phenolic, aromatic moiety. This modification resulted
in greatly improved biostability, as can be seen in Table 9, with
almost no significant accumulation of iodine radioactivity being
observed in the thyroids of rats treated with compound 46.[71]
meta-Iodobenzylguanidine (MIBG) – compound meta-47
(Figure 15) – is a widely used radioiodinated pharmaceutical in
nuclear medicine, both in therapy and diagnosis. While per-
forming lead optimization studies, aiming to find a powerful
imaging and therapeutic agent based on an iodobenzyl-
guanidine scaffold, Wieland and co-workers synthesized the
ortho/meta/para isomers of compound 47 and studied their
biodistribution profile in mice.[72] The accumulation of iodine
radioactivity in the thyroid (shown in Table 9) shows the para
isomer to be the fastest in dissociating from the radionuclide,
whereas deiodination is not an important metabolic pathway
for the meta isomer. The ortho isomer displays intermediate
behavior.
Table 9. Accumulation of iodine radioactivity in the thyroid for compounds 27, 46, and the isomers of compound 47.
2 min 15 min 0.5 h 1 h 2 h 3 h 24 h 48 h 72 h Ref.
27[a] n.a. n.a. n.a. 3.2 ± 0.98 n.a. 14 ± 2 19 ± 3 23 ± 6 n.a. [70]
46[b] 0.09 ± 0 0.04 ± 0.01 0.03 ± 0.01 0.03 ± 0 n.a. n.a. n.a. n.a. n.a. [71]
para-47[c] 0.5 (0.3–1.0) n.a. n.a. n.a. 0.9 (0.6–1.0) n.a. 9.0 (4.3–7.3) 13.6 (3.7–27.4) 33.6 (27.4–42.4) [72]
ortho-47[c] 0.3 (0.2–0.3) n.a. n.a. n.a. 0.4 (0.2–0.3) n.a. 2.6 (1.2–4.0) 9.4 (9.0–9.8) n.a. [72]
meta-47[c] 0.6 (0.5–0.7) n.a. n.a. n.a. 0.6 (0.5–0.6) n.a. 3.4 (2.1–4.7) 1.3 (0.5–2.1) n.a. [72]
[a] ID/organ %, rats, n = 4. [b] ID/organ %, rats, n = 4, 6, 5, 3. [c] ID/g %, dogs, n = 3.
Scheme 15. In vivo metabolism of MIBG (meta-47) as proposed by Rutgers[76] and Wafelman.[75] Rectangle: para isomer of MIBA, studied in vivo by Garg
et al.[77]
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Figure 15. Selected compounds bearing radioiodine on an aryl moiety.
To explain this result it is important to understand the me-
tabolism of iodobenzylguanidines. The groups of Wafelman[75]
and Rutgers[76] studied the metabolites formed after adminis-
tration of meta-47 (Scheme 15). Although the molecule was
mainly excreted intact (70–85 %), a small fraction was found to
undergo non-aromatic oxidative metabolism (Scheme 15a) to
give mostly meta-iodobenzoic acid (MIBA, meta-48) and meta-
iodohippuric acid (MIHA, 49),[75] which were minimally deiodin-
ated (see Table 10 for thyroid accumulation data for meta-48
studied alone).[77] In a very few patients they observed trace
amounts of aromatic oxidation (Scheme 15b), yielding the mi-
nor metabolite 4-hydroxy-3-iodobenzylguanidine (HMIBG, 50),
which was quickly deiodinated. The deiodination is likely per-
formed by IYD, metabolite 50 being structurally similar to an
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iodotyramine. Aromatic oxidation of the para isomer is likely to
result directly in loss of the radionuclide, explaining the faster
accumulation of iodine radioactivity in the thyroid. In addition,
compound para-47 will also form metabolites analogous to
those formed by meta-47 through the pathway depicted in
Scheme 15a, in the form of para-iodohippuric acid and para-
benzoic acid (compound para-48, shown in Scheme 15), which
are more rapidly deiodinated than their meta isomers, as shown
in Table 10.
Table 10. Accumulation of iodine radioactivity in the thyroid (mice) for com-
pounds para- and meta-48, expressed as ID/g %, n = 5, as reported by Garg
and co-workers.[77]
1 min 2 h 4 h 6 h
para-48 0.17 ± 0.04 0.20 ± 0.05 0.33 ± 0.09 0.38 ± 0.06
meta-48 0.13 ± 0.03 0.14 ± 0.03 0.23 ± 0.07 0.28 ± 0.04
Garg and co-workers studied the radionuclide dissociation of
the constitutional isomers of iodobenzoic acid (IBA; Scheme 15,
compounds meta- and para-48), and stated that its para isomer
is 1.5 times (until 6 h) more prone to deiodination than the
meta isomer (Table 10).[77] Their result is consistent with that
obtained before, when comparing the accumulation of iodine
radioactivity in the thyroid at 6 h p.i. of the meta and para
isomers of 47. Deiodination is less important for the isomers of
48 than for those of 47, because the metabolic products of IBA
are not likely to be further oxidized, so they may not be sub-
strates for IYD.
Substituent Effects – Electron-Withdrawing versus Electron-
Donating Groups
As anticipated before, it is likely that electron-donating substit-
uents are able to stabilize C–I bonds in iodoarenes in vivo. The
compounds in Figure 16 form a series from more electron-
donating to electron-withdrawing substituents on their aro-
matic ring, and their biostability (Table 11) decreases with
increasing electron-withdrawing character of the substituent.
Compound 51, in which the iodoarene moiety is linked to
an ether (EDG) is the biologically most stable (max ID/g %
thyroid = 0.13).[78] Shifting to a less strongly electron-donating
substituent (–CH2CH2NR2), as in compound 52, results in more
in vivo dehalogenation (max ID/g % thyroid = 0.58).[79] Further-
more, switching to an electron-withdrawing substituent
(–COOR, compound 53) drastically increases the rate of de-
iodination (max ID/g % thyroid = 2.97).[78] Compound 1, in
which the iodoaromatic moiety is embedded in a quinolinic
scaffold (capable of being protonated in vivo) and also bears a
very strongly EWG (–NO2), is very quickly deiodinated in vivo,
Table 11. Accumulation of iodine radioactivity in the thyroid for compounds 51, 52, 53, and 1.
5 min 1 h 2 h 4 h 6 h 8 h 12 h 16 h 24 h 48 h Ref.
51[a] n.a. 0.08 ± 0.01 n.a. 0.08 ± 0.02 n.a. 0.09 ± 0.04 n.a. n.a. 0.10 ± 0.04 0.13 ± 0.06 [78]
52[b] n.a. 0.19 ± 0.02 n.a. n.a. 0.20 ± 0.05 n.a. n.a. n.a. 0.58 ± 0.03 n.a. [79]
53[a] n.a. 0.94 ± 0.37 n.a. 1.34 ± 1.15 1.33 ± 0.56 n.a. n.a. 0.93 ± 0.45 2.97 ± 0.44 n.a. [78]
1[c] 0.19 ± 0.15 n.a. 4.7 ± 2.4 n.a. 11 ± 1 n.a. 14 ± 2 n.a. n.a. n.a. [16]
[a] ID/organ %, mice, n = 5. [b] ID/organ %, rats, n = 4. [c] ID/organ %, rats, n = 3.
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Figure 16. Selected compounds bearing radioiodine on the aromatic moiety,
from EDG (left) to EWG (right) substituents.
already displaying a very high uptake of iodine radioactivity in
the thyroid at 2.0 h p.i.[16]
DiMagno Method for Hampering Deiodination
DiMagno, of Ground Fluor Pharmaceuticals Inc., recently pat-
ented a method to reduce in vivo loss of radionuclide of
iodinated or astatinated aromatic pharmaceuticals.[80] His ra-
tionale is based on vicinal difluorination (around the radio-
nuclide, Figure 17), which, according to his findings, results in a
higher BDE of the carbon–radionuclide bond. Fluorine, despite
being a very electronegative halogen, has several unbound
electron pairs that are likely to be donated to the aromatic ring
through resonance, making the carbon–iodine bond stronger.
In addition, vicinal fluorination does not allow hydroxylation by
CYP450, avoiding the formation of metabolites that may un-
dergo deiodination through tautomerism or enzymatic deiodin-
ation by deiodinases.
Figure 17. Structures stabilized by vicinal difluorination.
3.2. Heterocycles
Indoles
Although indoles have been used as sites for labeling with ra-
dioiodine, in the synthesis of tracers for in vitro testing, as in
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the case of the melatonin analogue 54 (Scheme 16a),[81] they
do not find wide use in vivo,[82] most likely due to their chemi-
cal analogy with iodophenols, which makes them particularly
prone to in vivo deiodination. In fact, as shown in Scheme 16b,
compound 54 may tautomerize (like phenols), facilitating the
in vivo removal of iodide. Radioiodinated naltrindole analogue
55, bearing iodine on C-5, proved to be stable enough to be
used for ex vivo brain autoradiography in mice.[83] However, in
view of the fact that free radioiodide is actively pumped out of
the brain, deiodination of iodonaltrindole 55 might have es-
caped detection, because the autoradiographic analysis was
Scheme 16. (a) Selected radioiodinated indole compounds. (b) In vivo tau-
tomerism of compound 56.
Scheme 17. Mechanisms proposed by Goldberg and co-workers for the in vivo deiodination of iodohistidine: (a) through the formation of an ylide-carbene
leaving group, and (b) through tautomerism. (c) Selected compounds bearing radioiodine on thiophene and benzofuran moieties.
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performed exclusively on the brain. The same can be stated for
compound 56, which is a candidate for in vivo imaging of -
amyloid,[84] for which deiodination might be considered a negli-
gible side-reaction, while not hampering the analysis in the
brain, if it is assumed that deiodination is slow enough to allow
accumulation of the intact pharmaceutical to a detectable con-
centration.
Imidazoles
2-Iodinated imidazoles, as proposed by Goldberg and co-work-
ers, are biologically not stable, due to the decrease in the BDE
of the C–I bond upon protonation.[85] Goldberg's group pro-
posed two mechanisms for deiodination: in the mechanism de-
picted in Scheme 17a the driving force would be the formation
of an ylide-carbene leaving group, which should allow the nu-
cleophilic attack of a thiolate (present in vivo in cysteine-de-
pendent proteins, as GSH) to the iodine atom, whereas in
Scheme 17b tautomerism would instead be the kinetically limit-
ing step, as seen before. Goldberg envisaged the mechanism in
Scheme 17a, because they observed that methylation of N-3
was not preventing the reaction from occurring. Nevertheless,
they observed that an EWG at C-4 could hinder the deiodin-
ation, whereas the increase in basicity of the imidazole ring
should favor it, leaving this mechanism still not completely un-
derstood.
Benzofuran, Thiophene
Iodo-substituted thiophenes are biologically more stable than
their imidazole counterparts, as in the case of compound 57
(Scheme 17c)[86] but still seem to have the tendency to deiod-
inate quite quickly, as can be seen with compounds 58a and
58b,[87] shown in Table 12. Compounds 58a and 58b may un-
dergo enzymatic deiodination through the action of IYD, be-
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Table 12. Accumulation of iodine radioactivity in the thyroid for compounds 57–59.
Unit 5 min 10 min 0.5 h 45 min 1 h 2 h 24 h Ref.
57[a] ID/g % 0.12 ± 0.06 0.66 ± 0.32 1.51 ± 0.42[d] 2.88 ± 1.00 3.96 ± 0.87 9.17 ± 5.94 [86]
58a[b] ID/g % 15.57 50.58 109.68 [87]
(13.20–17.31) (37.97–75.23) (81.37–166.09)
ID/organ % 0.19 0.57 2.25 [87]
(0.16–0.20) (0.41–0.83) (2.16–2.39)
58b[b] ID/g % 12.51 26.26 36.45 [87]
(7.87–16.51) (5.03–36.88) (31.90–39.98)
ID/organ % 0.13 0.28 1.24 [87]
(0.08–0.17) (0.05–0.38) (0.99–1.40)
59[c] ID/organ % 0.06 0.03 0.02 0.02 0.08 0.358 [88]
(0.05–0.07) (0.02–0.03) (0.01–0.02) (0.01–0.02) (0.04–0.11) (0.259–0.422)
[a] Rats, n = 3. [b] Rats, n = 2. [c] Rats, n = 3. [d] 20 min.
cause they share some structural similarities with iodotyramine.
Furthermore, their oxidative metabolism may lead to the forma-
tion of metabolites that may deiodinate very rapidly. Oxidative
metabolism also could explain why compound 57 is more re-
sistant to dehalogenation than 58ab. In fact, 57 is much larger
than 58ab, and oxidation is likely to occur on parts of the mol-
ecule other than the iodothiophene moiety, avoiding the for-
mation of deiodinating metabolites. With the same reasoning
the improved biostability of the analogue 58b relative to that
of analogue 58a could also be explained. Analogue 58b carries
a bulky iPr group, which is also likely to hinder the metabolic
enzymes sterically.
Iodobenzofuran seems a promising site for the radioiodin-
ation of pharmaceuticals for use in vivo: compound 59
(Scheme 17c) is perfectly stable up to 4 h, and radioactivity in
the thyroid rises only after a long residence time in the body
(24 h),[88] due to slow accumulation and organification of radio-
iodine in the thyroid. Despite the promising profile, there are
not many literature examples of successful radiotracers based
on this moiety.
3.3. Vinyl
As mentioned before in the Introduction, in the choice of radio-
iodination site in the design of a radioiodinated tracer, sp2
carbon atoms are chosen over sp3 ones because of the higher
Figure 18. Selected compounds bearing radioiodine on terminal vinyl moieties.
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BDE of the C–I bond formed. Also, as seen in the above subsec-
tion, some electron-rich iodoaromatic moieties are well toler-
ated in vivo. However, in the design of radioiodinated tracers,
in cases in which deiodination of an iodoaromatic fragment is
of concern, or the iodination results in an analogue that is less
potent than the parent compound, the radioactive iodine can
be inserted on a vinylic carbon atom, generally on the terminus
of an allyl moiety, yielding compounds such as those presented
in Figure 18.
The iodoallyl moiety would seem to be particularly conve-
nient in the design of radioiodinated pharmaceuticals, because
– in addition to being particularly resistant in vivo, due to the
high BDE of the bond formed between the iodine atom and an
sp2 carbon atom – it can be directly added to a nucleophilic
center present in an already known molecule. For instance,
compound 60 is a derivative of diprenorphine functionalized
with an iodoallyl moiety introduced at a very late stage of the
synthesis. Lever and co-workers claim to have used compound
60 to image peripheral opioid receptors successfully in mice.[83]
The same group anticipated that compound 61, an iodoallyl
derivative of naltrindole, could be used to image Δ-opioid re-
ceptors (DORs) in mouse brain selectively, showing a better
pharmacokinetic and pharmacological profile than its iodo-
aromatic analogue 55.[90]
As discussed in the Section 2, iodoallyl moieties may un-
dergo oxidation by CYP450 enzymes with consequent loss of
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the radionuclide, due to the reactivity of the metabolite formed.
This effect is more marked for compounds 62, 63, and 65 (see
Table 13), in which the iodoallyl label is in each case attached
to an sp3 nitrogen atom. Compound 63 in particular, after very
promising in vitro results,[91] was not selected for further studies
due to a poor in vivo profile.[83] Compound 64, in which the
iodoallyl label is attached to an oxygen atom, proved to be
biologically slightly more stable than its analogue 65
(Scheme 16).[78] The nitrogen atom might activate the oxidative
metabolism of the iodoallyl fragment; hence, in the design of
new radioiodinated pharmaceuticals bearing such a labeling
moiety, an oxygen atom would be preferred over an sp3 nitro-
gen atom as anchoring site.
Table 13. Accumulation of iodine radioactivity in the thyroid for compounds
62, 64, and 65.
30 min 1 h 4 h 48 h Ref.
62[a] 0.27 ± 0.11 n.a. 2.29 ± 0.54 n.a. [89]
64[b] n.a. 0.35 ± 0.14 0.52 ± 0.32 1.99 ± 0.20 [78]
65[b] n.a. 0.27 ± 0.14 0.33 ± 0.12 2.34 ± 0.24 [78]
[a] ID/organ %, rats, n = 5. [b] ID/organ %, rats, n = 5.
3.4. Aliphatic
Compounds bearing iodine atom on an aliphatic carbon atom
are particularly prone to in vivo deiodination, due to the low
BDE of the C–I bond. The loss of the radionuclide is likely due
to oxidation of the halogenated carbon atom by CYP450 en-
zymes, as described in Section 2. Radiopharmaceuticals bearing
radioactive iodine on an sp3 carbon atom are uncommon; how-
ever, some research compounds are shown in Figure 19. Com-
pound 3 is rapidly deiodinated (>90 % after 5 min p.i.), whereas
its extended analogue 66, as well as 4, in which a methylene
group at C-4 is substituted by an oxygen atom, both showed
greatly improved biological profiles (>90 % of the ID retained
the radionuclide at 5 h p.i.).[25] Compound 66 may be absorbed
Figure 19. Selected compounds bearing radioiodine on an sp3 carbon atom.
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and metabolized exactly like a fatty acid and may hide the ra-
dioiodinated terminal carbon atom at the center of a micelle,
thus avoiding the terminal hydroxylation that would result in
deiodination. The γ-oxygen atom in iodohexanoic acid ana-
logue 4 is likely to block the terminal hydroxylation of the iod-
inated carbon atom.
Analogously to the -iodoethoxy group, the -iodoethyl-
amide fragment was successfully used by Chalon's group to
obtain the neuroimaging agent 67, which was only very mildly
deiodinated: accumulation of iodine radioactivity in rat thyroid
increased from 0.37 (ID/organ %) at 0.5 h p.i. to 2.41 at 5 h.[92]
After this promising result, Wyffels and co-workers synthesized
the anandamide analogues 2 and 68.[17] Unfortunately, those
compounds were rapidly deiodinated (>45 and >60 %, respec-
tively), as confirmed by ex vivo radio-HLPC analysis of plasma
extractions. Interestingly, in the brain 95 % of the total ex-
tracted radioactivity was due to free iodide, meaning either that
the deiodination was so fast as to allow iodide to accumulate
in brain, or that the deiodination itself occurred in the brain.
Most likely compounds 2 and 68, being very similar analogues
of the endogenous neurotransmitter anandamide, underwent
metabolic transformations specific to the endogenous substrate
directly in the brain, either resulting in loss of the radionuclide
or yielding radioactive metabolites that were retained nonspe-
cifically in the brain.
Compound 69 (Figure 19) bears the iodine atom on an
unusual cubane polycyclic fragment that proved to be resistant
to in vivo deiodination.[93] The iodocubane is likely not to be
oxidized efficiently by liver enzymes, due to its unusual three-
dimensional structure. Also, it is particularly bulky, blocking any
possible nucleophilic attack on the halogenated carbon atom.
The iodinated tamoxifen analogue 70 (Figure 19), despite bear-
ing the halogen atom on an alkyl chain, turned out to be stable
enough in vivo (Table 14) to be used to image expression of
estrogen receptors. In fact, compound 70 has several aromatic
moieties that are more likely to undergo oxidative metabolism
by CYP450 enzymes than the halogenated carbon atom.[94]
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Table 14. Accumulation of iodine radioactivity in the thyroid for compounds 69 and 70.
15 min 45 min 1 h 2 h 3 h 6 h 24 h Ref.
69[a] 0.28 ± 0.01 0.21 ± 0.01 n.a. 0.25 ± 0.03 n.a. n.a. n.a. [93]
70[b] n.a. n.a. 0.393 ± 0.121 0.748 ± 0.076 0.776 ± 0.111 0.696 ± 0.225 0.493 ± 0.122 [94]
[a] ID/organ %, rats, n = 5. [b] ID/g %, rats, n = 3.
3.5. Summary and Discussion
In this section several radioiodinated tracers have been col-
lected according to the chemical nature of the iodination site.
The data on the accumulation of iodine radioactivity in the
thyroid have been extracted from biodistribution and pharma-
cokinetic in vivo studies published in peer-reviewed journals.
Fast accumulation of iodine radioactivity in the thyroid has
been taken as a measure of deiodination. The deiodination rate
of each pharmaceutical analyzed has been correlated with the
specific structural features of the iodination site and of the
whole molecule, modeling the biological pathways that those
radioiodinated pharmaceuticals were likely to undergo to lead
to deiodination. Arenes were defined to be the biologically
most stable site for radioiodination. Biostability may be in-
creased through attachment of an electron-donating substitu-
ent (e.g., OCH3) to the aromatic ring. Radioiodination on phen-
ols, anilines, heterocycles (excluding benzofuran), and aliphatic
carbon atoms yielded, in most cases, biologically unstable struc-
tures, which in vivo showed partial or complete loss of the
radionuclide. Often, each molecule represents a case to be stud-
ied individually, because the whole structure is likely to affect
the metabolic pathways the radioiodinated pharmaceutical
might undergo. Alternatively, iodoallyl fragments have been
successfully incorporated into already known drugs, yielding
biologically stable labeled analogues that could be used for ex
vivo autoradiography or in vivo imaging.
4. Radioiodinated Peptides and Proteins
Recently, interest in radioiodine-labeled peptides and anti-
bodies has increased. Their high specificity and low toxicity pro-
files make them useful tools in nuclear medicine.
The iodine radionuclide is commonly incorporated into a
peptide chain either through direct iodination of an aromatic
moiety or by indirect chemical ligation with an iodinated pros-
thetic group. In the case of direct iodination, phenylalanine is
hard to deiodinate because of the highly electron-rich character
of its aromatic ring. The sulfenyl iodide moiety, formed by radio-
iodination of cysteine, undergoes fast non-enzymatic deiodina-
tion. Radioiodination of tryptophan is not carried out, not only
because of the biological instability of the iodoindole deriva-
tive, as discussed in the previous section, but also because dur-
ing oxidative iodination it undergoes hydrolysis and side-oxid-
ation reactions resulting in the formation of an unstable oxind-
ole.[95] Radioiodinated tyrosine and histidine are more stable; of
these, tyrosine is preferred because of the milder conditions
needed to introduce the iodine and its stability towards
non-enzymatic deiodination.[96] Radioiodinated aliphatic amino
acids are hardly applied because of the low bond dissociation
energy (BDE) of the C–I bond formed with an sp3 carbon atom.
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Lysine, arginine, glutamate, and aspartate residues are not com-
monly radioiodinated; however, their side chains can be used
as anchor points to introduce prosthetic groups carrying the
radionuclide. Serine and threonine are not as nucleophilic as
lysine, and conjugation onto those fragments with a radio-
iodinated label would need reaction conditions unsuitable for
delicate macromolecules such as antibodies. Some artificial
amino acids incorporating radioiodine on ad hoc designed lat-
eral chains have been developed (generally iodine is substi-
tuted on a vinylic carbon atom), but they are deployed individu-
ally as tracers or therapeutic agents in oncology, rather than
being incorporated in peptides.[97]
In the following subsections the most important findings in
the design of radioiodinated peptides for in vivo studies are
reviewed: the different strategies that medicinal chemists have
developed to overcome in vivo deiodination of radioiodinated
peptides are outlined, and examples of successfully radio-
iodinated peptides and radioiodinated tracers are given. It is
important to note that, apart from the radioiodination site, the
pharmacology of the whole labeled peptide may also affect the
deiodination rate.
4.1. Radioiodine on Tyrosine Moieties
As described by Geissler,[98] Bakker,[99] and Foulon,[100] peptides
incorporating radioiodinated tyrosine residues are not suscepti-
ble per se to enzymatic deiodination. For instance, Geissler's
group came across the first evidence of this when they synthe-
sized the Tyr 125I-labeled monoclonal antibody DA4-4 (71; Fig-
ure 20). This particular antibody, having reached its target, was
internalized, and after internalization, mostly non-target signals
were observed. The mechanism is depicted in Scheme 18a. This
research group discovered that the cellular decrease in radioac-
tivity over time was mostly related to proteolytic catabolism in
the internal lysosomes upon internalization of the antibody–
target complex.[98] Enzymatic deiodination could take place
only once the iodo-Tyr moieties had been released as single
free amino acid units. Similar findings were obtained by Bakker
on determining the pharmacokinetic/pharmacodynamic profile
of the radiolabeled 123I-Tyr3-octreotide 72 (Figure 20). This cy-
clic peptide contains two D-amino acids, making it more resist-
ant to proteolysis.[99b] Metabolic studies by the same research
group showed that most of the peptide was excreted intact,
and the residual non-specific radioactivity was mostly repre-
sented by the drug itself, which was undergoing normal clear-
ance by the liver and the kidneys.[99a] Abnormal radioactivity in
the thyroid could be observed only at 24–48 h p.i., meaning
that the deiodination process was taking place after a slow
proteolytic catabolism.
Microreview
Scheme 18. (a) Internalization of a monoclonal antibody radiolabeled by conventional techniques. (b) Internalization of a monoclonal antibody radiolabeled
by the technique developed by Stein and co-workers.
Figure 20. Selected strategies for radiolabeling a peptide by installing radioio-
dine on a Tyr moiety.
Foulon and co-workers designed a terminal pentapeptidic
group containing a 131I-D-tyrosine residue and consisting of D-
amino acids, which was fused to an anti-EGFRvIII monoclonal
antibody, yielding the antibody derivative 73 (Figure 21).[100]
The rationale behind their design is that proteolytic metabolism
of an antibody bound to its target cannot be prevented, thus
at least the radioiodinated label has to be stable towards prote-
olysis and has to be retained in the lysosomes. The radio-
iodinated labels NH2–KR*YRR–OH and NH2–D-KR*YRR–OH each
contained three positively charged amino acids, because previ-
ous works[101] had suggested that positively charged metabo-
lites were retained much longer in the lysosomes without being
released in the cytoplasm. The use of D-amino acids further
prevented proteolysis, as was demonstrated by the fact that
when tested in vivo, most of the labeled peptide 73 was ex-
creted intact. Thus, the combined effect of the major retention
in the lysosome (resulting from the positively charged amino
acids) and the improved proteolytic stability (conferred by the
incorporation of D-amino acids) resulted in an improved signal-
to-noise profile compared to previous efforts with different ra-
dioiodinated labels, enabling successful imaging of EGFRvIII by
full-body SPECT.
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Figure 21. Selected strategies for radiolabeling a peptide by installing radioio-
dine on a Tyr moiety.
While designing smaller peptides for use directly as tracers,
Sun and co-workers[102] discovered that the t-Boc-protected
YG5 peptide 74 (Figure 21) was markedly more stable towards
deiodination than its unprotected analogue. The particular fea-
ture of this peptide is that the radiolabeled tyrosine residue
is terminally located, spaced by five glycine moieties from the
pharmacophore (the RGD sequence). This terminal position
means that the labeled tyrosine residue is exposed to dehalo-
genases or proteases, but introducing the t-Boc group on the
amine terminus of YG5, as in 74, likely prevented the peptide
from being metabolized, allowing it to be used as a radiotracer.
Wall and his research group assayed a peptide p5 labeled
with a radioiodinated tyrosine residue near the N-terminus, but
not as the last amino acid, in compound 75 (Figure 21).[103]
Peptide p5 is not an antibody – it is much smaller – but is
believed to bind strongly to its target (amyloid plaques) in a
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similar fashion. The complex of p5 with the amyloid plaques
does not undergo proteolysis (i.e., is not internalized), due to
the intrinsic resistance of amyloid plaques to proteolysis, as op-
posed to unbound 75, which undergoes fast body clearance.
Recording the residual radioactivity of the bound complex al-
lowed use of the peptide as a radiotracer. It is important to
mention that the peptide–target complex does not undergo
deiodination, thus differing from the fate of the complex
formed by the antibody DA4-4 (71) and its target, the lysosomal
proteolysis of which, as seen before, is unavoidable.[98] This ob-
servation illustrates the concept that every radioiodinated
peptidic tracer makes its own case, needing the medicinal
chemist to design each probe according to the fate that the
peptide and the possible complex between the peptide and its
target are likely to meet.
Stein and co-workers developed a labeling strategy to cir-
cumvent the problem of release of radioiodide from the target
cell after internalization and digestion of the radioiodinated
antibody in the lysosomes.[104] This labeling approach is shown
in Figure 22 and features a label (peptide 76) to be conjugated
to the antibody. Compound 76 is a tetrapeptide containing the
two functionalized DTPA prosthetic groups 77 and the two
maleimide moieties 78. The DTPA moieties, attached to the ε-
amino branch of two D-lysine residues, facilitate the retention
of the radiolabel in the lysosome: they each carry several carb-
oxylic acid functionalities, which are known to react in the
lysosome with nucleophilic fragments (mechanism depicted in
Scheme 18b). The D-amino acids in the tripeptide prevent the
radiolabel being cleaved from the DTPA moiety, and as a result
the radioactive catabolites are retained in the lysosomes of the
target cell. The para-NCS-benzyl group was introduced to adjust
the hydrophobicity of the molecule in order to improve the
uptake into tumor cells. Radioiodine was installed onto the D-
tyrosine moiety (red in Figure 22) and onto the maleimido moi-
Figure 22. Strategy for radiolabeling a peptide by installing radioiodine on a
functionalized Tyr-containing moiety as described by Stein and co-work-
ers.[104]
Scheme 19. Formation of the lysine conjugate with the Bolton–Hunter reagent 79.
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eties (double bond highlighted blue in Figure 22). The latter
were introduced ad hoc to improve the radioiodination yield.
This probe represents the current state of the art for labeling
antibodies with a residualizing radioiodine label. Tumor-to-
blood and tumor-to-muscle ratios were 10 times higher when
the radiolabeling strategy of Stein and co-workers was applied
than they were when the same antibody was labeled by
conventional radioiodination techniques (i.e., chloramine-T
method).
4.2. Radioiodine on Prosthetic Groups
The cases analyzed until now mostly relate to the radioiodina-
tion of a tyrosine moiety. In the literature, though, there are
several examples based on prosthetic groups, commonly an
iodinated aromatic acyl moiety, attached to a nucleophilic lat-
eral chain, such as through the nitrogen atom in lysine
(Scheme 19). Obviously, the main drawback of this method is
that the acylation site must not involve its pharmacophore. It
is mostly exploited in the labeling of longer peptides or mono-
clonal antibodies, because these are large globular proteins that
can tolerate modification, as long as the prosthetic groups are
conjugated far away from the recognition epitopes.
One of the first, and most widely used, methods to perform
peptide labeling of lysine is the conjugation with a Bolton–
Hunter reagent of type 79 (Scheme 19).[105] Russell and co-
workers compared the use of the Bolton–Hunter reagents with
the iodination carried out on nonspecific tyrosine moieties, and
found the Bolton–Hunter reagent conjugates to be more resist-
ant to deiodination than the tyrosine labeling products.[106] Al-
though they did not further investigate the factors affecting
deiodination, nor the effect of the position in the peptide in
which modification was occurring, it can be assumed that the
lysine conjugate (Scheme 19) does not undergo proteolytic
cleavage, preventing the release of radioiodinated Bolton–
Hunter label. However, the nonconjugated Bolton–Hunter rea-
gents share many of structural features with 4-iodo-
tyrosine, being very likely good substrates for deiodinases.
In the course of defining the scope of different labeling
methods for peptides, Garg's group compared the biostability
towards deiodination of peptides 80c and 80d (Figure 23), la-
beled with meta-48 (MIBA), with that of peptides 80a and 80b
(Figure 23), in which iodine was introduced directly on an
iodotyrosyl moiety. Modifications in the nearby amino acid se-
quence were then introduced, to investigate whether the
neighboring amino acids would affect the deiodination rate of
the iodine-bearing label.[107] These modifications consisted of
changing a methionine residue for a norleucine one and the
insertion of a D-amino acid (80a and 80c are the parent
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peptides; 80b and 80d are their modified analogues). The
methionine modification was assayed to investigate the
hypothesis of a neighboring deiodination effect by a nearby
thiol moiety, whereas the D-amino acid was inserted to improve
the proteolytic stability of the modified analogues. For the two
tyrosine-labeled peptides 80a and 80b, fast accumulation of
radioiodide in the thyroid was observed, whereas the two pept-
ides 80c and 80d, labeled with meta-48, gave superb signal-to-
noise ratios. Radioiodide accumulation in the thyroid could be
observed only a long time after injection. The main radioactive
metabolite of 80a and 80b was reported to be free radioiodide,
whereas for peptides 80c and 80d the radioactivity was mostly
excreted as lysine labeled with MIBA. No significant difference
between the altered-sequence peptides was observed, proba-
bly because the neighboring deiodinating effect by the thiol
moieties might have been observed only when placed exactly
next to the iodine label. In addition, the D-amino acids were
introduced quite far from the iodinated moiety, which did not
prevent proteolysis of the label.
Figure 23. Selected lysine conjugates formed with derivatives of iodobenzoic
acid 48.
Conjugates 81–83 (Figure 23) are lysine derivatives labeled
with aromatic acyl moieties, which are charged at physiological
pH.[101a,108] Conjugate 81 proved to be negatively charged even
at lysosomal pH, whereas 82 and 83 are positively charged.
No important accumulation in the thyroid was observed after
injection of the bioconjugate derivatives 81–83, making them
good candidates for use in clinical radiology. The biostability
towards deiodination is most likely given by the capability of
the radioiodinated label to be retained in the lysosome, being
charged at lysosomal pH. Nevertheless, because the acylation
is likely to happen on the most exposed fragments on the sur-
face of the protein, the three-dimensional structure may isolate
the labeled fragments from the surrounding matrix, avoiding
contact with the solvent or free fragments that may interact
with the radioiodinated moiety.
4.3. Summary and Discussion
The results reviewed in this section indicate that proteolysis
plays a major role – even more important than that played by
deiodinases – in the deiodinating catabolism of radioiodinated
peptides and proteins. It is an aspect that is still not completely
understood and one that would need further studies. It is, how-
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ever, possible to define a few rules for the design of radioiod-
inated peptidic tracers.
Iodination on tyrosine moieties is the most effective peptide
labeling technique, because it involves a non-peptidic modifica-
tion that would normally not affect the conformation of the
pharmacophore. However, if the labeled tyrosine residue and
its iodination state are essential to the pharmacophore, another
labeling technique must be identified. It is important to know
the fate of the peptide once it reaches its target: if the complex
is likely to undergo internalization and subsequent proteolysis
in the lysosomes, it is crucial either to prevent the proteolysis
or to force the catabolites not to be released in the cytoplasm.
Proteolysis can be avoided by incorporating the Tyr in a
peptidomimetic feature such as inside a cyclic structure (as in
the case of compound 72) or among non-proteinogenic amino
acids (compound 73). Monoclonal antibodies, which are inter-
nalized upon reaching their target, can instead be conjugated
to a radioiodinated label, which – upon internalization and sub-
sequent degradation – is not released in the cytoplasm as ra-
dioactive catabolites, being designed to be retained in the lyso-
some (as in the cases of labels 73, 76, 81, 82, and 83). If this is
not possible, because it would affect the pharmacology of the
probe, an iodinated tyrosine unit can be attached to a poly-
glycine spacer terminally protected with t-Boc (as in the case
of compound 74) to prevent proteolysis. If none of those modi-
fications are tolerated or it is not possible to introduce them
efficiently, the use of a prosthetic group bearing the
radionuclide can be envisaged (as in the cases of labels 79 and
meta-48). When the peptide–target complex is not subject to
proteolytic degradation, simple radioiodination of tyrosine frag-
ments (as in radiolabeled peptide 75) will be more useful, be-
cause the unbound probes will be cleared out, removing non-
target signals. Finally, it is important to avoid directly neighbor-
ing thiol-containing amino acids, because they would intra-
molecularly remove the iodine as mentioned in Section 2. Fur-
thermore, there is evidence that the use of radioiodinated
metabolically stable tyrosine analogues does not yield antibody
conjugates that can be successfully used as tracers, because
upon proteolytic cleavage the free amino acid would diffuse
non-specifically to non-target tissues, lowering the signal-to-
noise ratio in the analysis.[53]
This section reviews some of the most important and recent
advances in the design of radiolabeled peptides and proteins
with radioactive iodine. Different strategies (direct iodination
and prosthetic-group conjugation) are discussed with particular
focus on the factors that may affect the dissociation of the ra-
dioiodine from the tracer. The main factor involved is identified
as the proteolytic cleavage of the radioiodine label; no on-pept-
ide deiodination is observed. Thus, some strategies to improve
the surrounding of the radioiodine to improve the metabolic
stability are discussed. Finally, it has become clear that the strat-
egy to be deployed has to be adapted to each particular drug,
because – to design the appropriate probe – it is necessary to
understand the metabolic fate of the whole radiolabeled drug.
Lastly, further studies might be directed towards clear under-
standing of the role of deiodinases and proteolytic cleavage
during the in vivo deiodination of radiolabeled peptides.
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5. General Guidelines
A number of factors need to be taken into account in the de-
sign of radioiodinated pharmaceuticals to improve biostability
towards in vivo deiodination.
The deiodination rate is determined by the physiochemical
properties of the whole molecule. In this review we have also
aimed to identify the impact of the physiochemical properties
of the iodination site. In Subsection 5.1 we review the factors
relating to the composition of the whole molecule that may
affect the deiodination rate. In Subsection 5.2, the structural
and chemical composition of the radioiodination sites and the
correlation with the rate of deiodination are analyzed. On the
basis of this analysis, the radioiodination sites are classified as
resistant or not resistant towards in vivo deiodination. Finally,
an example of design strategy is discussed, with the derived
guidelines and the knowledge gathered in this review being
applied in the rational design of a radioiodinated pharmaceuti-
cal with improved biostability towards in vivo deiodination.
5.1. Analysis of the Whole Molecule
It is crucial to understand how the whole molecule is metabo-
lized, because metabolic transformations of other groups may
affect the deiodination rate, even though they would not ap-
pear to affect the reactivity of the C–I bond directly. Generally,
xenobiotics are metabolized to less lipophilic derivatives to fa-
cilitate their excretion through the kidneys. Metabolic transfor-
mations on the same moiety as used for radioiodination are
likely to result in cleavage of the C–I bond, either through direct
deiodination (as in the case of deiodination of iodotyramine-/
iodothyronine-like molecules catalyzed by DIOs/IYD and of acti-
vated para-iodoanilines by CYP450 enzymes, as shown in Sec-
tion 2), or through formation of deiodinating metabolites (as in
the cases of oxidation of alkyl and vinyl iodides, activated ortho-
iodoanilines, or compound meta-47, as shown in Subsections
2.3 and 2.4 and in Scheme 15b in Subsection 3.1, respectively).
When a metabolic transformation is not directed at the radio-
iodination site, two main kinds of metabolites can be defined:
deiodinating and non-deiodinating.
Deiodinating metabolites are radioiodinated metabolites
that either dehalogenate spontaneously under physiological
conditions (e.g., α-hydroxy halides such as 14 in Scheme 10) or
are substrates for deiodinating enzymes (e.g., MIBG metabolite
50 in Scheme 15b, ortho-iodoanilines as shown in Scheme 14,
or peptides such as 71 in Figure 20, which release MIT upon
proteolytic catabolism).
Non-deiodinating metabolites are radioiodinated com-
pounds that have been transformed into less lipophilic metabo-
lites without the physicochemical properties of the C–I bond
being affected; they are less likely to be further metabolized at
the radioiodination site, avoiding further deiodination.
Compound 84a (Figure 24), for instance, was deiodinated
twice as rapidly as its metabolite 84b, as shown in the biodistri-
bution study by Hagimori and co-workers reported in Table 15,
in which 84a and 84b were tested separately.[109] The deiodin-
ation of compound 84a likely involved oxidative metabolism,
because it was importantly accumulated early p.i. in the liver
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and in the lung (tissues rich in CYP450 enzymes), whereas com-
pound 84b was accumulated at a much slower rate. Hagimori
and co-workers also observed that compound 84a was metabo-
lized in the serum to 84b, so the higher accumulation of the
radioiodine in the thyroid may be related to early deiodina-
tion of the parent compound 84a, before it was completely
hydrolyzed in the serum to 84b. Hypothetically, inhibiting the
hydrolysis of the ethyl ester in the serum, or replacing the ethyl
ester with a non-hydrolyzable lipophilic bioisostere (e.g. 3-ethyl-
1,2,4-oxadiazole), could result in an analogue less resistant than
compound 84a, because the analogue would undergo more
oxidative metabolism, also of the radioiodinated site.
Figure 24. Compounds tested by Hagimori and co-workers.[109]
The metabolic profile of the non-iodinated analogue of the
radioiodinated pharmaceutical of interest may give useful infor-
mation for directing radioiodination to a site not already known
to be oxidized by CYP450 enzymes or generally not modified
in vivo. If another moiety in the molecule of interest, far from
the radioiodination site, is known to be metabolized, it is likely
that the metabolite will be more resistant than the parent com-
pound (e.g., compound 84a). More broadly, decreasing the
C log P value for the system of interest (i.e., obtaining less lipo-
philic analogues, as shown for estradiol analogue 20a in Sub-
section 2.3, Figure 7, or in the text above for compound 84b),
may reduce the extent of metabolism by oxidative deiodin-
ation, yielding more resistant analogues. If the pharmacology
of the compound does not allow less lipophilic analogues, the
presence of other apolar moieties that are better substrates
than the radioiodinated carbon atom for oxidation by CYP450
enzymes may decrease the oxidative deiodination (as shown in
Subsection 3.4 for tamoxifen analogue 70 (Figure 19) the three
aryl moieties of which are more likely to be oxidized than an
iodinated sp3 carbon atom, or for compound 4 (Figure 2) in
which the γ-oxygen atom makes -oxidation of the carboxylic
acid more likely than the deiodinating hydroxylation of the
iodinated carbon atom). Furthermore, steric hindrance and bulk
around the iodination site were found to yield more resistant
radioiodinated pharmaceuticals, because the radioiodinated
moiety is less accessible to the metabolic enzymes (as in the
case of compound 69). When deiodination is carried out by
DIOs or IYD enzymes, the use of more constrained scaffolds
yields more resistant radioiodinated pharmaceuticals (as in the
case of morphine analogue 31). The specific pharmacology and
pharmacokinetic profile of the radioiodinated pharmaceutical
may affect the deiodination rate, as observed in Subsection 3.4
for compound 66. This does not substantially differ from natu-
rally occurring fatty acids and is likely metabolized as such.
Compound 66, once injected, is likely to be transported in the
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body in micelles, with the terminal halide hidden at the center.
Hence, the -oxidation of the carboxylic polar head (as a natu-
rally occurring fatty acid) is more likely to occur rather than the
hydroxylation of the hidden terminal iodinated carbon atom.
Also, it is important to consider the fate of the radioiodinated
pharmaceutical. For instance, radioiodinated peptides that un-
dergo internalization and proteolysis by the target cell can be
radioiodinated through specifically designed moieties that will
be retained in the target, avoiding the release of deiodinating
metabolites.
Radioiodinated pharmaceuticals acting in the central nerv-
ous system, crossing the BBB, might not be hindered by de-
iodination unless the deiodination rate outside the brain is
faster than the pharmacokinetics of the compound (i.e., no ra-
dioactive compound can reach its target in the brain), or the
deiodination takes place inside the brain (i.e., iodide is not
cleared rapidly enough from the brain, hampering the analysis).
5.2. Analysis of the Radioiodination Site
The structural features of the iodinated radiopharmaceuticals
covered in this review are collected here, and their resistance
or lack of resistance towards in vivo deiodination is briefly re-
sumed.
Radioiodinated sp2 carbon atoms often yield C–I bonds that
are more resistant towards in vivo deiodination than sp or sp3
carbon atoms.
Iodoarenes and iodovinyl systems are generally resistant to-
wards in vivo deiodination.
meta-Iodoarenes are generally more resistant than their
ortho or para isomers towards in vivo deiodination.
Iodoanilines are often not resistant towards in vivo deiodin-
ation. meta-Iodoanilines are more resistant than their ortho or
para isomers.
Iodophenols, especially ortho-iodophenols, are often not
resistant to in vivo deiodination. Non-strained and non-bulky
iodotyramines in particular are not resistant towards in vivo
deiodination.
Electron-donating groups (e.g. methoxy, methyl, ...) on iodo-
arenes generally yield compounds resistant towards in vivo
deiodination.
Electron-withdrawing groups (e.g., nitro, carboxyl, ...) on io-
doarenes generally yield compounds not resistant towards in
vivo deiodination.
Difluorination in the vicinity of the radioiodine generally
yields iodoarenes that are more resistant towards in vivo de-
iodination.
Iodovinyl moieties are often deployed in the form of iodoallyl
fragments used to radioiodinate a nucleophilic oxygen or nitro-
gen atom. When an oxygen rather than a nitrogen atom has
been iodoallylated, the resulting compounds have generally
been more resistant towards in vivo deiodination.
Radioiodinated heterocycles are often not resistant to in
vivo deiodination. Radioiodinated nitrogen-containing (e.g.,
quinozalines, indoles, or imidazoles) and sulfur-containing (e.g.,
thiophenes) heterocycles are generally not resistant towards in
vivo deiodination. Radioiodinated oxygen-containing heterocy-
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cles (e.g., benzofurans) are one of the few classes of iodinated
heterocyclic moieties to be resistant to in vivo deiodination.
Radioiodination on sp3 carbon atoms should yield radio-
iodinated compounds that are resistant towards in vivo de-
iodination when: (i) other, more accessible lipophilic fragments
are present, (ii) the sp3 carbon atom is embedded in a bulky
(e.g., cubane) moiety, or (iii) the radioiodine is inserted in the
form of a 2-iodoethoxy or (2-iodoethyl)amino moiety.
5.3. Example of Rational Design, Design of Radioiodinated
THC Analogues
Here the derived guidelines and the knowledge gathered in
this review are applied to the rational design of iodinated phar-
maceuticals with improved in vivo biostability towards de-
iodination. The following molecules were chosen, because they
are abundant natural products [i.e., complex molecules that can
easily be obtained and functionalized (radioiodinated)]. Also,
the corresponding “cold” iodinated analogues of those natural
products are already known and have been pharmacologically
tested, allowing us to rationally infer why no “hot” analogue
has ever been tested in vivo and which rational modification
we would apply to improve the in vivo profiles of such radio-
pharmaceuticals.
Compound 85, Δ9-tetrahydrocannabinol (Δ9-THC;
Scheme 20a), is the principal psychoactive ingredient in Canna-
bis sativa. The recent difficulties encountered by Bial Pharma-
ceutics in developing pharmaceuticals targeting the endo-
cannabinoid system[110] shed light on the lack of knowledge
relating to the differences in pharmacology and pharmaco-
kinetics between synthetic and natural occurring cannabinoids.
A short (1 h) biodistribution study, deploying a 5′-radiofluorin-
ated analogue of 86, through PET and plasma radioactivity
count, was successfully performed by Charalambous and co-
workers.[111] Notably, they could observe evidence of defluorin-
ation of their analogue. No radioiodinated analogues of 85 or
86 could successfully be deployed to image the cannabinoid
system, making it difficult to study the long-lasting pharmaco-
logical effects of those naturally occurring compounds. “Cold”
iodinated analogues in the form of compounds 87 and 88 were
synthesized and tested, both in vitro and in vivo, in a SAR (struc-
ture–activity relationship) study by Compton and co-work-
ers.[112] Structural modifications geared towards the study of
the pharmacological activity of 85 have often been performed
on a cannabinoid scaffold such as compound 86, which has
pharmacological effects comparable with those of 85, but was
reported to be chemically more stable.[113] No imaging studies
deploying radioiodinated analogues of THC have been pub-
lished to date, presumably due to poor in vivo profiles of radio-
iodinated compounds 87 and 88 as tracers, which may have
been detected in pilot studies. The poor in vivo profiles could
be explained by in vivo metabolic deiodination, which can be
elucidated and overcome by using the guidelines outlined
above.
In compound 87 (Scheme 20a), the iodine atom is installed
on a substituted arene, an ortho-iodophenol, a structure that
has been seen before (Subsection 3.2.2) and shown to have
Microreview
Scheme 20. (a) Selected cannabinoid analogues. (b) Tautomerism of analogue 87. (c) Proposed mechanism for the in vivo deiodination of compound 88.
(d) Iodinated analogues of compound 86 that might show improved in vivo profiles in relation to compounds 87 and 88.
potential to deiodinate. In view of the bulky strained three-
dimensional structure of compound 87, and the lack of
ionizable anchor points, it is unlikely that it might be a substrate
for deiodinases, so a supposed poor in vivo profile could be a
consequence of interaction between nucleophilic moieties (e.g.,
the thiol terminus of a cysteine) and the reactive tautomer of
compound 87 (shown in Scheme 20b). Shifting the position of
the iodine atom on the aromatic ring (from 2 to 4) might help
to circumvent the deiodination side-reaction; however, substi-
tution at the 4-position of THC is already known to suppress
any bioactivity.[113] For this reason 4-substitution with an elec-
tron-donating group is not useful either; therefore, to design a
radioiodinated analogue of compound 86 that may be biologi-
cally stable, another site for radioiodination must be chosen.
In compound 88 (Scheme 20a) the iodine atom was installed
on a terminal sp3 carbon atom of a linear pentyl moiety, a struc-
ture that has been seen before (Subsection 2.3.2) and has the
potential to undergo oxidative deiodinating metabolism by
CYP450 enzymes. These would oxidize the 5′-position, resulting
in a very unstable α-hydroxy halide, which would quickly deiod-
inate to yield the corresponding aldehyde (Scheme 20c). Com-
pound 85 is known also to undergo oxidative metabolism at
the 7-, 8-, 9-, 10-, and 11-positions in humans, as shown by
Watanabe and co-workers;[114] therefore, radioiodination at
those positions could also yield analogues likely to show poor
in vivo profiles, due to deiodination by oxidative metabolism.
Deiodination originating from oxidation by CYP450 enzymes at
the 5′-position can be circumvented by deploying the strategies
shown above (Subsection 3.5): that is, by installing a -iodo-
ethoxy group, as in analogue 89 (Scheme 20d), or iodine on a
bulky three-dimensional structure (e.g., a cubane), as in ana-
logue 90 (Scheme 20d). Alternatively, radioiodine can be in-
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stalled through an sp2 carbon atom in a terminal vinyl or allyl
moiety, as shown before (Subsection 3.4), generating analogues
such as 91 or 92 (Scheme 20d).
Analogues 89–92, generated according to the guidelines in
this review, could potentially be deployed as SPECT or PET in
vivo tracers because of their hypothesized improved resistance
towards in vivo deiodination, in relation to the already known
iodinated compounds 87 and 88. The use of 89–92 could allow
the study of the long-term interactions of the natural occurring
compounds such as 85 and 86 with the endocannabinoid sys-
tem through in vivo imaging.
5.4. Synthesis of Radioiodinated Pharmaceuticals
Because radioiodination reactions of pharmaceuticals have
been extensively reviewed elsewhere,[115] here we only briefly
summarize the techniques most commonly used to insert radio-
iodine onto the scaffolds considered in this review to be most
resistant towards in vivo deiodination (i.e., radioiodinated vin-
ylic carbon atoms and electron-rich arenes). Radioiodine iso-
topes (*I) are generally purchased as Na*I solutions in aqueous
NaOH. The iododestannylation of a trialkyltin precursor (com-
pounds such as 93 and 94 in Scheme 21a) is the preferred
synthetic route, allowing iodine to be inserted with high regio-
selectivity. In the case of particularly strongly activated arenes
(compounds such as 95), electrophilic substitution is also a
viable route (Scheme 21b).[115] In both iododestannylation and
electrophilic substitution, *I+ is generated in situ from Na*I in
the presence of an oxidizing agent, to displace a leaving group
(the trialkylstannyl group and a proton, respectively). Com-
monly used oxidizing agents are hydrogen peroxide, peracetic
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acid, dichloramine T, and Iodo-Gen® (Scheme 21, rounded
square).[115] The trialkyltin precursor is often obtained through
radical hydrostannylation of an alkyne 96 with R′3SnH or
through Pd0-catalyzed substitution of a trialkyltin group onto a
halogenated arene 97.
Scheme 21. Commonly used reactions and reagents for the radioiodination
of pharmaceuticals.
Keywords: Radiolabeling · Isotopic labeling · Radioiodinated
pharmaceuticals · Iodine · Metabolism
[1] L. Fowden, R. Robinson, Proc. Roy. Soc. B 1968, 171, 5–18.
[2] O. Dohán, A. De la Vieja, V. Paroder, C. Riedel, M. Artani, M. Reed, C. S.
Ginter, N. Carrasco, Endocr. Rev. 2003, 24, 48–77.
[3] S. Venturi, M. Venturi, Nutr. Health 2009, 20, 119–134.
[4] L. S. Zuckier, O. Dohan, Y. Li, C. J. Chang, N. Carrasco, E. Dadachova, O.
Dohan, J. Nucl. Med. 2004, 45, 500–507.
[5] H. F. Cserr, B. J. Berman, Am. J. Physiol. 1978, 235, F331–F337.
[6] Y.-A. Ma, C. J. Sih, A. Harms, J. Am. Chem. Soc. 1999, 121, 8967–8968.
[7] A. C. Bianco, P. R. Larsen, Thyroid 2005, 15, 777–786.
[8] K. Sorimachi, N. Ui, Biochim. Biophys. Acta 1974, 342, 30–40.
[9] S. R. Thomas, P. M. McTamney, J. M. Adler, N. LaRonde-LeBlanc, S. E.
Rokita, J. Biol. Chem. 2009, 284, 19659–19667.
[10] a) R. J. Robinson, R. W. P. Cutler, A. V. Lorenzo, C. F. Barlow, J. Neurochem.
1968, 15, 1169–1179; b) R. J. Robinson, R. W. P. Cutler, A. V. Lorenzo, C. F.
Barlow, J. Neurochem. 1968, 15, 455–458.
[11] a) H. F. Cserr, B. J. Berman, Am. J. Physiol. 1978, 235, F331–F337; b) H.
Davson, J. R. Hollingsworth, J. Physiol. 1973, 233, 327–347; c) F. L. Eng-
strom, S.-Y. Chow, J. W. Kemp, D. M. Woodbury, Epilepsia 1984, 25, 518–
525.
[12] a) M. W. Bradbury, H. E. Brøndsted, J. Physiol. 1973, 234, 127–143; b) T.
Okamura, J. Igarashi, T. Kikuchi, K. Fukushi, Y. Arano, T. Irie, Life Sci. 2009,
84, 791–795.
[13] C. Spitzweg, W. Joba, W. Eisenmenger, A. E. Heufelder, J. Clin. Endocrinol.
Metab. 1998, 83, 1746–1751.
[14] C. Renier, H. Vogel, O. Offor, C. Yao, I. Wapnir, J. Neuro-Oncol. 2010, 96,
331–336.
[15] L. A. Everett, B. Glaser, J. C. Beck, J. R. Idol, A. Buchs, M. a. Heyman, F.
Adawi, E. Hazani, E. Nassir, A. D. Baxevanis, V. C. Sheffield, E. D. Green,
Nat. Genet. 1997, 17, 411–422.
[16] A. Biegon, C. A. Mathis, S. M. Hanrahan, W. J. Jagust, Brain Res. 1993,
619, 236–246.
[17] L. Wyffels, S. De Bruyne, P. Blanckaert, D. M. Lambert, F. De Vos, Bioorg.
Med. Chem. 2009, 17, 49–56.
[18] H. H. Coenen, J. Mertens, B. Mazière, in Radioiodination Reactions for
Radiopharmaceuticals, Springer, The Netherlands, 2006, pp. 5–16.
[19] R. C. West, D. R. Lide, in CRC Handbook of Chemistry and Physics, 70th
ed., CRC Press, Cleveland, Ohio, 1989, p. D-190.
Eur. J. Org. Chem. 2017, 3387–3414 www.eurjoc.org © 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim3413
[20] P. R. Wells, Prog. Phys. Org. Chem. 1968, 6, 111–145.
[21] H. H. Coenen, J. Mertens, B. Mazière, in Radioiodination Reactions for
Radiopharmaceuticals, Springer, The Netherlands, 2006, pp. 17–28.
[22] T. Clark, M. Hennemann, J. S. Murray, P. Politzer, J. Mol. Model. 2007, 13,
291–296.
[23] K. E. Riley, J. S. Murray, J. Fanfrlík, J. Řezáč, R. J. Solá, M. C. Concha, F. M.
Ramos, P. Politzer, J. Mol. Model. 2011, 17, 3309–3318.
[24] a) M. Kolář, J. Hostaš, P. Hobza, Phys. Chem. Chem. Phys. 2014, 16, 9987–
9996; b) M. H. Kolář, P. Deepa, H. Ajani, A. Pecina, P. Hobza, in Halogen
Bonding II: Impact on Materials Chemistry and Life Sciences (Eds.: P. Me-
trangolo, G. Resnati), Springer International Publishing, Cham, 2015, pp.
1–25.
[25] S. Hamant, J.-P. Mathieu, C. Morin, I. Trimcev, M. Vidal, Bioorg. Med. Chem.
Lett. 1994, 4, 1687–1690.
[26] C. M. Won, Pharm. Res. 1992, 09, 131–137.
[27] M. L. Rosene, G. Wittmann, R. Arrojo e Drigo, P. S. Singru, R. M. Lechan,
A. C. Bianco, Endocrinology 2010, 151, 5961–5970.
[28] G. G. J. M. Kuiper, M. H. A. Kester, R. P. Peeters, T. J. Visser, Thyroid 2005,
15, 787–798.
[29] M. M. Kaplan, R. D. Utiger, J. Clin. Invest. 1978, 61, 459–471.
[30] U. Schweizer, C. Schlicker, D. Braun, J. Kohrle, C. Steegborn, Proc. Natl.
Acad. Sci. USA 2014, 111, 10526–10531.
[31] D. Manna, G. Mugesh, Angew. Chem. Int. Ed. 2010, 49, 9246–9249; Angew.
Chem. 2010, 122, 9432.
[32] C. A. Bayse, E. R. Rafferty, Inorg. Chem. 2010, 49, 5365–5367.
[33] D. Manna, G. Mugesh, J. Am. Chem. Soc. 2012, 134, 4269–4279.
[34] I. Callebaut, C. Curcio-Morelli, J.-P. Mornon, B. Gereben, C. Buettner, S.
Huang, B. Castro, T. L. Fonseca, J. W. Harney, P. R. Larsen, A. C. Bianco, J.
Biol. Chem. 2003, 278, 36887–36896.
[35] K. Goto, D. Sonoda, K. Shimada, S. Sase, T. Kawashima, Angew. Chem. Int.
Ed. 2010, 49, 545–547; Angew. Chem. 2010, 122, 555.
[36] P. M. McTamney, S. E. Rokita, J. Am. Chem. Soc. 2009, 131, 14212–14213.
[37] M. Kunishima, J. E. Friedman, S. E. Rokita, J. Am. Chem. Soc. 1999, 121,
4722–4723.
[38] S. E. Rokita, J. M. Adler, P. M. McTamney, J. A. Watson Jr., Biochimie 2010,
92, 1227–1235.
[39] D. Reinwein, J. E. Rall, J. Biol. Chem. 1966, 241, 1636–1643.
[40] N. H. P. Cnubben, J. Vervoort, M. G. Boersma, I. M. C. M. Rietjens, Biochem.
Pharmacol. 1995, 49, 1235–1248.
[41] H. Tachizawa, T. L. MacDonald, R. A. Neal, Mol. Pharmacol. 1982, 22, 745–
751.
[42] F. P. Guengerich, P. S. Mason, W. T. Stott, T. R. Fox, P. G. Watanabe, Cancer
Res. 1981, 41, 4391–4398.
[43] C. Neto, M. Oliveira, L. Gano, F. Marques, I. Santos, G. Morais, T. Yasuda,
T. Thiemann, F. Botelho, C. Oliveira, Curr. Radiopharm. 2009, 2, 83–91.
[44] L. Olsen, C. Oostenbrink, F. S. Jørgensen, Adv. Drug Delivery Rev. 2015,
86, 61–71.
[45] W. Daily, E. Hawkins, D. Klaubert, J. Liu, P. Meisenheimer, M. Scurria, J. W.
Shultz, J. Unch, K. V. Wood, W. Zhou, Patent WO2006130551 A8, 2007.
[46] M. V. Papadopoulou, W. D. Bloomer, H. S. Rosenzweig, S. R. Wilkinson, M.
Kaiser, Eur. J. Med. Chem. 2014, 87, 79–88.
[47] M. C. Feiters, A. E. Rowan, R. J. M. Nolte, Chem. Soc. Rev. 2000, 29, 375–
384.
[48] J. Kirchmair, A. H. Goller, D. Lang, J. Kunze, B. Testa, I. D. Wilson, R. C.
Glen, G. Schneider, Nat. Rev. Drug Discovery 2015, 14, 387–404.
[49] J. E. Sinsheimer, T. Wang, S. Röder, Y. Y. Shum, Biochem. Biophys. Res.
Commun. 1978, 83, 281–286.
[50] T. L. Macdonald, M. W. Anders, CRC Crit. Rev. Toxicol. 1983, 11, 85–120.
[51] C. Zhang, J. R. Kenny, H. Le, A. Deese, K. A. Ford, L. K. Lightning, P. W.
Fan, J. P. Driscoll, J. S. Halladay, C. E. C. A. Hop, S. C. Khojasteh, Chem.
Res. Toxicol. 2011, 24, 1668–1677.
[52] J. Owens, A. A. Tebbutt, A. L. McGregor, K. Kodama, S. S. Magar, M. E.
Perlman, D. J. Robins, G. J. Durant, J. McCulloch, Nucl. Med. Biol. 2000,
27, 557–564.
[53] C. Krummeich, M. Holschbach, G. Stöcklin, Appl. Radiat. Isot. 1994, 45,
929–935.
[54] R. E. Counsell, T. D. Smith, V. V. Ranade, O. P. Noronha, P. Desai, J. Med.
Chem. 1973, 16, 684–687.
[55] N. P. Verhoeff, A. Bekier, H. F. Beer, P. A. Schubiger, P. Fennema, E. A.
van Royen, Nucl. Med. Commun. 1993, 14, 137–144.
Microreview
[56] K. Kawai, Y. Fujibayashi, H. Saji, J. Konishi, A. Kubodera, A. Yokoyama, Int.
J. Radiat. Appl. Instrum. B 1990, 17, 369–376.
[57] G. L. Patrick, in An introduction to medicinal chemistry, 5th ed., Oxford
University Press, Lavis, Italy, 2013.
[58] J. A. M. Tafani, Y. Lazorthes, B. Danet, J. C. Verdie, J. P. Esquerre, J. Simon,
R. Guiraud, Int. J. Radiat. Appl. Instrum. B 1989, 16, 505–509.
[59] N. Shikano, K. Kawai, L. G. Flores, R. Nishii, N. Kubota, N. Ishikawa, A.
Kubodera, J. Nucl. Med. 2003, 44, 625–631.
[60] A. F. M. Siu, R. M. Lambrecht, J. Shani, S. G. Pyne, L. A. P. Kane-Maguire,
J. Labelled Compd. Radiopharm. 1997, 39, 711–729.
[61] G. Bormans, D. Huyghe, A. Christiaen, K. Verbeke, T. de Groot, H. Vanbil-
loen, P. de Witte, A. Verbruggen, J. Labelled Compd. Radiopharm. 2004,
47, 191–198.
[62] S. W. Kim, J. H. Park, S. D. Yang, M. G. Hur, C. W. Choi, K. H. Yu, Bull.
Korean Chem. Soc. 2008, 29, 2023–2025.
[63] H. F. Kung, Y.-Z. Guo, J. Billings, X. Xu, R. H. Mach, M. Blau, R. E. Ackerhalt,
Int. J. Radiat. Appl. Instrum. B 1988, 15, 195–201.
[64] C. Höltke, M. P. Law, S. Wagner, H.-J. Breyholz, K. Kopka, C. Bremer, B.
Levkau, O. Schober, M. Schäfers, Bioorg. Med. Chem. 2006, 14, 1910–1917.
[65] M. Hirata, Y. Kanai, S. Naka, K. Matsumuro, S. Kagawa, M. Yoshimoto, Y.
Ohmomo, Ann. Nucl. Med. 2011, 25, 117–124.
[66] H. F. Kung, S. Newman, S.-R. Choi, S. Oya, C. Hou, Z.-P. Zhuang, P. D.
Acton, K. Plössl, J. Winkler, M.-P. Kung, J. Med. Chem. 2004, 47, 5258–
5264.
[67] S. Oya, S.-R. Choi, C. Hou, M. Mu, M.-P. Kung, P. D. Acton, M. Siciliano,
H. F. Kung, Nucl. Med. Biol. 2000, 27, 249–254.
[68] Z.-P. Zhuang, S.-R. Choi, C. Hou, M. Mu, M.-P. Kung, P. D. Acton, H. F. Kung,
Nucl. Med. Biol. 2000, 27, 169–175.
[69] M. Hirata, Y. Kanai, S. Naka, K. Matsumuro, S. Kagawa, M. Yoshimoto, Y.
Ohmomo, Ann. Nucl. Med. 2012, 26, 381–389.
[70] C. M. Thonoor, M. W. Couch, D. M. Greer, K. D. Thomas, C. M. Williams, J.
Nucl. Med. 1988, 29, 1668–1674.
[71] J. Billings, M.-P. Kung, S. Chumpradit, S. Pan, H. F. Kung, Life Sci. 1989,
45, 771–718.
[72] D. M. Wieland, J.-l. Wu, L. E. Brown, T. J. Mangner, D. P. Swanson, W. H.
Beierwaltes, J. Nucl. Med. 1980, 21, 349–353.
[73] D. H. Burns, R. E. Gibson, R. F. Dannals, in Nuclear Imaging in Drug Discov-
ery, Development and Approval, Birkhäuser Basel, Boston, Massachusetts,
1992, chapter 6.
[74] B. Allolio, A. Schirbel, S. Hahner, Patent EP2712631 A1, 2014.
[75] A. R. Wafelman, C. A. Hoefnagel, H. J. M. Maessen, R. A. A. Maes, J. H.
Beijnen, Eur. J. Nucl. Med. Mol. Imaging 1997, 24, 544–552.
[76] M. Rutgers, C. K. M. Buitenhuis, C. A. Hoefnagel, P. A. Voûte, L. A. Smets,
Int. J. Cancer 2000, 87, 412–422.
[77] P. K. Garg, S. K. Slade, C. L. Harrison, M. R. Zalutsky, Int. J. Radiat. Appl.
Instrum. B 1989, 16, 669–673.
[78] R. N. Waterhouse, J. Chapman, B. Izard, A. Donald, K. Belbin, J. C. O'Brien,
T. L. Collier, Nucl. Med. Biol. 1997, 24, 587–593.
[79] C. S. John, M. E. Gulden, B. J. Vilner, W. D. Bowen, Nucl. Med. Biol. 1996,
23, 761–766.
[80] S. G. DiMagno, Patent US20140275539 A1, 2014.
[81] B. Stankov, B. Cozzi, V. Lucini, P. Fumagalli, F. Scaglione, F. Fraschini, Neu-
roendocrinology 1991, 53, 214–221.
[82] V. Motilva, J. Cabeza, C. La Lastra, Curr. Pharm. Des. 2001, 7, 909–931.
[83] J. Lever, Curr. Pharm. Des. 2007, 13, 33–49.
[84] H. Watanabe, M. Ono, M. Haratake, N. Kobashi, H. Saji, M. Nakayama,
Bioorg. Med. Chem. 2010, 18, 4740–4746.
[85] E. R. Goldberg, L. A. Cohen, Bioorg. Chem. 1993, 21, 41–48.
[86] R. N. Waterhouse, J. T. Gotsick, G. W. Kabalka, M. M. Goodman, J. C.
O'Brien, Nucl. Med. Biol. 1998, 25, 77–80.
[87] M. M. Goodman, G. W. Kabalka, R. C. Marks, F. F. Knapp, J. Lee, Y. Liang,
J. Med. Chem. 1992, 35, 280–285.
Eur. J. Org. Chem. 2017, 3387–3414 www.eurjoc.org © 2017 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim3414
[88] M.-P. Kung, H. F. Kung, J. Billings, Y. Yang, R. A. Murphy, A. Alavi, J. Nucl.
Med. 1990, 31, 648–654.
[89] D. Guilloteau, P. Emond, J.-L. Baulieu, L. Garreau, Y. Frangin, L. Pourcelot,
L. Mauclaire, J.-C. Besnard, S. Chalon, Nucl. Med. Biol. 1998, 25, 331–337.
[90] J. R. Lever, W. B. Mathews, R. L. Allmon, C. M. Kinter, P. A. Rauseo, U.
Scheffel, J. Labelled Compd. Radiopharm. 2003, 46, S36.
[91] R. N. Waterhouse, M. J. Campa, J. Park, E. F. Patz, J. Labelled Compd.
Radiopharm. 1998, 41, 801–810.
[92] S. Chalon, Y. Frangin, D. Guilloteau, M. Caillet, C. Guimbal, M.-H. Schmitt,
G. Desplanches, J.-L. Baulieu, J.-C. Besnard, Int. J. Radiat. Appl. Instrum. B
1990, 17, 389–395.
[93] R. Al Hussainy, J. Verbeek, D. van der Born, A. H. Braker, J. E. Leysen, R. J.
Knol, J. Booij, J. K. D. M. Herscheid, J. Med. Chem. 2011, 54, 3480–3491.
[94] D. J. Yang, C. Li, L. Kuang, J. E. Price, A. U. Buzdar, W. Tansey, A. Cherif,
M. Gretzer, E. Edmund Kim, S. Wallace, Life Sci. 1994, 55, 53–67.
[95] N. M. Alexander, J. Biol. Chem. 1974, 249, 1946–1952.
[96] A. Vértes, S. Nagy, Z. Klencsár, R. G. Lovas, F. Rösch, in Handbook of Nu-
clear Chemistry, Springer, Boston, MA, USA, 2010, pp. 2131–2132.
[97] J. McConathy, W. Yu, N. Jarkas, W. Seo, D. M. Schuster, M. M. Goodman,
Med. Res. Rev. 2012, 32, 868–905.
[98] F. Geissler, S. K. Anderson, P. Venkatesan, O. Press, Cancer Res. 1992, 52,
2907–2915.
[99] a) W. H. Bakker, E. P. Krenning, W. a. Breeman, P. P. Kooij, J. C. Reubi, J. W.
Koper, M. de Jong, J. S. Laméris, T. J. Visser, S. W. Lamberts, J. Nucl. Med.
1991, 32, 1184–1189; b) W. H. Bakker, E. P. Krenning, W. a. Breeman, J. W.
Koper, P. P. Kooij, J. C. Reubi, J. G. Klijn, T. J. Visser, R. Docter, S. W. Lam-
berts, J. Nucl. Med. 1990, 31, 1501–1509.
[100] C. F. Foulon, C. J. Reist, D. D. Bigner, M. R. Zalutsky, Cancer Res. 2000,
60, 4453–4460.
[101] a) C. J. Reist, G. E. Archer, C. J. Wikstrand, D. D. Bigner, M. R. Zalutsky,
Cancer Res. 1997, 57, 1510–1515; b) C. J. Reist, P. K. Garg, K. L. Alston,
D. D. Bigner, M. R. Zalutsky, Cancer Res. 1996, 56, 4970–4977.
[102] X. Sun, T. Chu, X. Liu, X. Wang, Appl. Radiat. Isot. 2006, 64, 645–650.
[103] E. B. Martin, S. J. Kennel, T. Richey, C. Wooliver, D. Osborne, A. Williams,
A. Stuckey, J. S. Wall, Peptides 2014, 60, 63–70.
[104] R. Stein, S. V. Govindan, M. J. Mattes, S. Chen, L. Reed, G. Newsome,
B. J. McBride, G. L. Griffiths, H. J. Hansen, D. M. Goldenberg, Cancer Res.
2003, 63, 111–118.
[105] A. E. Bolton, W. M. Hunter, Biochem. J. 1973, 133, 529–538.
[106] J. Russell, J. A. O'Donoghue, R. Finn, J. Koziorowski, S. Ruan, J. L. Humm,
C. C. Ling, J. Nucl. Med. 2002, 43, 671–677.
[107] P. K. Garg, K. L. Alston, P. C. Welsh, M. R. Zalutsky, Bioconjugate Chem.
1996, 7, 233–239.
[108] S. Shankar, G. Vaidyanathan, D. J. Affleck, K. Peixoto, D. D. Bigner, M. R.
Zalutsky, Nucl. Med. Biol. 2004, 31, 909–919.
[109] M. Hagimori, T. Murakami, K. Shimizu, M. Nishida, T. Ohshima, T. Mukai,
MedChemComm 2016, 7, 1003–1006.
[110] E. von Schaper, Nat. Biotechnol. 2016, 34, 223–223.
[111] A. Charalambous, G. Marciniak, C.-Y. Shiue, S. L. Dewey, D. J. Schlyer,
A. P. Wolf, A. Makriyannis, Pharmacol. Biochem. Behav. 1991, 40, 503–
507.
[112] D. R. Compton, K. C. Rice, B. R. De Costa, R. K. Razdan, L. S. Melvin,
M. R. Johnson, B. R. Martin, J. Pharmacol. Exp. Ther. 1993, 265, 218–226.
[113] A. Charalambous, S. Lin, G. Marciniak, A. Banijamali, F. L. Friend, D. R.
Compton, B. R. Martin, A. Makriyannis, Pharmacol. Biochem. Behav.
1991, 40, 509–512.
[114] K. Watanabe, S. Yamaori, T. Funahashi, T. Kimura, I. Yamamoto, Life Sci.
2007, 80, 1415–1419.
[115] H. H. Coenen, J. Mertens, B. Mazière, in Radioiodination Reactions for
Radiopharmaceuticals, Springer, The Netherlands, 2006, pp. 73–86.
Received: December 22, 2016
